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Abstract: -Fast Facts (abbreviated) [Words = 425] 
Definition:  Obesity is multifactorial, resulting from genetic, 
epigenetic, physiological, behavioural, sociocultural and environmental 
influences which produce an imbalance between energy intake and 
expenditure over an extended time period. 
Etiology:  Obesity occurs in genetically susceptible individuals under a 
variety of environmental influences.   
Natural history:  Physiologic processes resist weight loss and produce a 
"settled" weight within a given environment.  Weight loss produces 
metabolic adaptation (lower energy expenditure) and alterations in 
appetite signals that promote food intake.  Persons with obesity struggle 
to lose weight and regain is common. 
Prevention:  The environment of developed countries is obesogenic.  
Environmental change is the responsibility of societies.  For individuals 
with obesity and no associated health risk, advise self-help approaches.  
Iatrogenic weight gain: Many medications have been associated with weight 
gain (insulin, sulfonylureas, antidepressants, antipsychotics and 
others).  For patients at-risk, avoid them, or prescribe weight neutral 
alternatives. 
In medical practices, weight management is indicated for individuals with 
BMI >30kg/m2 or >25kg/m2 with an obesity associated comorbidity, 
including increased waist circumference. 
Lifestyle Change: For many patients, changing behaviours requires skill 
training and use of behavioural tools (self-monitoring of food intake, 
physical activity and body weight; environmental control; contingency 
planning). 
Diet:  Many diets have been shown to produce and sustain weight loss, if 
they are followed.  There is no magic diet.  Choose a diet that the 
patient will follow and which has health benefits.   
Physical Activity:  Give a specific prescription describing the 
frequency, intensity, time and type. For weight loss, recommend minimum 
goal of 150 min/week.  For prevention and maintenance, recommend 250-300 
minutes per week is recommended.  
Medicating for weight loss is indicated for individuals with BMI >30kg/m2 
or >27kg/m2 with an obesity associated comorbidity.  Medications approved 
in the US/EU are orlistat, naltrexone/ bupropion and liraglutide.  In the 
US, lorcaserin and phentermine/topiramate are also available.   Use the 
following principles: 
*Medications work by enhancing adherence to diet. 
*Lifestyle is the foundation.  Don't prescribe medications alone. 
*All medications have different safety profiles that must be matched to 
the patient's profile. 
*Every medication will not work in every patient.  Stop the medication 
and try another if 4-5% weight loss does not occur in 3-4 months [In 
obese diabetic patients >3% weight loss can be considered satisfactory]. 
*Use medications long term to sustain lost weight. 
 
Surgical management is indicated for individuals with BMI >40kg/m2 or 
>35kg/m2 with an obesity associated comorbidity.  The three most common 
procedures are gastric banding, sleeve gastrectomy, and Roux-en Y gastric 
bypass.   These procedures have been shown to produce remarkable health 
improvement and to reduce mortality.  Life-long care is indicated to 
address nutritional needs long-term.  
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Manuscript
Fast Facts (abbreviated) [Words = 425] 
Definition:  Obesity is multifactorial, resulting from genetic, epigenetic, physiological, 
behavioural, sociocultural and environmental influences which produce an imbalance 
between energy intake and expenditure over an extended time period. 
Etiology:  Obesity occurs in genetically susceptible individuals under a variety of 
environmental influences.   
Natural history:  Physiologic processes resist weight loss and produce a “settled” 
weight within a given environment.  Weight loss produces metabolic adaptation 
(lower energy expenditure) and alterations in appetite signals that promote food 
intake.  Persons with obesity struggle to lose weight and regain is common. 
Prevention:  The environment of developed countries is obesogenic.  Environmental 
change is the responsibility of societies.  For individuals with obesity and no 
associated health risk, advise self-help approaches.  
Iatrogenic weight gain: Many medications have been associated with weight gain 
(insulin, sulfonylureas, antidepressants, antipsychotics and others).  For patients at-
risk, avoid them, or prescribe weight neutral alternatives. 
In medical practices, weight management is indicated for individuals with BMI 
>30kg/m2 or >25kg/m2 with an obesity associated comorbidity, including 
increased waist circumference. 
Lifestyle Change: For many patients, changing behaviours requires skill training 
and use of behavioural tools (self-monitoring of food intake, physical activity and 
body weight; environmental control; contingency planning). 
Diet:  Many diets have been shown to produce and sustain weight loss, if they are 
followed.  There is no magic diet.  Choose a diet that the patient will follow and which 
has health benefits.   
Physical Activity:  Give a specific prescription describing the frequency, intensity, 
time and type. For weight loss, recommend minimum goal of 150 min/week.  For 
prevention and maintenance, recommend 250-300 minutes per week is 
recommended.  
Medicating for weight loss is indicated for individuals with BMI >30kg/m2 or 
>27kg/m2 with an obesity associated comorbidity.  Medications approved in 
the US/EU are orlistat, naltrexone/ bupropion and liraglutide.  In the US, 
lorcaserin and phentermine/topiramate are also available.   Use the following 
principles: 
• Medications work by enhancing adherence to diet. 
• Lifestyle is the foundation.  Don’t prescribe medications alone. 
• All medications have different safety profiles that must be matched to the 
patient’s profile. 
• Every medication will not work in every patient.  Stop the medication and try 
another if 4-5% weight loss does not occur in 3-4 months [In obese diabetic 
patients >3% weight loss can be considered satisfactory]. 
• Use medications long term to sustain lost weight. 
 
Surgical management is indicated for individuals with BMI >40kg/m2 or 
>35kg/m2 with an obesity associated comorbidity.  The three most common 
procedures are gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass.   
These procedures have been shown to produce remarkable health improvement and 
to reduce mortality.  Life-long care is indicated to address nutritional needs long-
term.  
 
 
Search strategy and selection criteria 
A search for original articles and reviews published between January 1990 and 
August 2015 focusing on obesity management was performed in PubMed and 
MEDLINE using the following search terms (or combination of terms): “obesity”, 
“weight loss”, “management”, “treatment”, “guidelines”, “recommendations”, “costs”, 
“outcomes”, “comorbidity or comorbidities”, “body composition”, “life-style 
intervention”, “physical activity”, “exercise”,  “pharmacotherapy”, “medication”, “anti-
obesity drugs”, “bariatric surgery” and “metabolic surgery”. Only English-language, 
full-text articles were included. Very recent references from September 2015 were 
also identified and selected. Articles in journals with explicit policies governing 
conflicts-of-interest, and stringent peer-review processes were favoured. Data from 
larger replicated studies with longer periods of observation when possible were 
systematically chosen to be presented. More weight was given to randomized 
controlled trials, prospective case–control studies, meta-analyses and systematic 
reviews. 
Background/Introduction: (Word Count = 376) 
Over the past 50 years obesity has become an international public health 
problem that impacts the quality of life, increases the risk of illness and raises health 
care costs in countries in all parts of the world (Appendix Figure 1). 1-6   
Appendix Figure 1 Worldwide prevalence of Obesity in men 
Measurement of obesity in these surveys is done with the body mass index (BMI), 
[wt(kg)/Ht(m2)]  which has a modestly good correlation with body fat . 7  The BMI has 
the advantage of simplicity in epidemiological studies, but it has deficiencies since it 
does not separate fat from lean body mass. 8 Thus, BMI should be considered a 
screening measurement rather than a diagnostic tool.  Additional measurements are 
needed to complement the BMI and should include waist circumference (or 
Waist/Height ratio). 9, 10 Both variables are strong predictors of health risk. 9, 10  
Ethnic differences in waist circumference need to be considered in its clinical use. 11  
In addition to measures of central adiposity it is desirable to measure blood pressure, 
glucose and lipids (HDL-cholesterol and triglycerides).  
Obesity is expensive 12, 13 and along with diabetes is a disease that needs to 
be “defused”. 14  Medical costs rise progressively as BMI increases 15 and are 
expected to continue to rise in the next 15 years. 16 17  Obesity is second only to 
depression in its cost to employers. 18 
Obesity has a multifactorial nature resulting from genetic, epigenetic, 
physiological, behavioural, sociocultural and environmental influences that lead to an 
imbalance between energy intake and expenditure over an extended time period. 
Recently, the importance of less sleep, endocrine disruptors – such as some 
chemicals in food packaging and foods – increased time in climate controlled areas, 
cessation of smoking, weight gain that is associated with some medications 
(described in more detail later), older parental age at birth as well as intrauterine and 
intergenerational effects have been highlighted as contributors to the obesity 
epidemic.19, 20  
 Obesity shortens life span 21 and impacts the function of many organ systems 
21, 22, 23 (Appendix Figure 2).   This mortality results from several diseases that are 
associated with obesity, including diabetes, chronic kidney disease, gastro-intestinal 
disease and cardiovascular disease.  
Appendix Figure 2 Mortality versus BMI 
 Body weight is defended, meaning that maintaining weight loss is often 
difficult or unsuccessful. 24   
Management of the Patient with Obesity (Word count = 171) 
 The rising prevalence of obesity worldwide cries out for preventive strategies 
to defuse the future health and economic costs of this problem. Economic and 
technological changes in the environment have driven the obesity epidemic 28, and 
many studies have tested strategies in schools, in work-sites and in the community 
that might prevent progression of BMI, but so far, these efforts have had limited 
impact 26, 27 and the evidence for effective economic policies to prevent obesity 
remains limited. 28   
When prevention fails, as it will for many people, treatment is indicated.   To 
guide health care professionals in treating the problem effectively a number of 
guidelines have been developed both in the US, 29, 30, 31  in the UK 32 and in 
Europe.33, 34   We will use these guidelines as the basis for outlining therapy for 
obesity which can include lifestyle changes, dietary modification, increased physical 
activity, the use of medications and in some cases the recommendation for surgery.  
Lifestyle Changes (Word Count = 485):   
The cornerstone for treatment of the patient with obesity in the US, UK and 
Europe is a Comprehensive, or Multi-component Lifestyle Intervention. 29, 30, 32, 35    
The term comprehensive refers to simultaneous implementation of three strategies: 
lifestyle or behavioural training, dietary change to reduce energy intake, and an 
increase in physical activity.  The evidence supporting the efficacy of lifestyle 
intervention or behavioural modification is supported, in part, by data from 2 large 
randomized clinical trials: the Look AHEAD 36 and the Diabetes Prevention Program. 
37   Three variables, including number of behavioural sessions attended, number of 
meal replacements used and the weekly minutes of physical activity all predicted 
weight loss at 1, 4, and 8 years  in the Look AHEAD study and these are 
summarized for the 8 year data in 3 of the 4 panels in Figure 1.  A systematic review 
of evidence showed that if these components are delivered in at least 14 face-to-face 
(group or individual) sessions over six months with treatment continuing to one year, 
average observed weight loss is 8 kg. 29  While this may seem modest, it translates 
into clinically significant improvements in blood pressure, triglycerides, HDL 
cholesterol, measures of glycaemic control and reduction in risk for progression to 
type 2 diabetes. 29    Based on these and other findings, the US Preventive Services 
Task Force 38 has recommended that obese individuals with cardiovascular disease 
(CVD) risk factors should be referred for lifestyle treatment and the US Center for 
Medicare and Medicaid Services promoted policies to reimburse providers for 
intensive behavioural therapy for the patient with obesity. 39   In the UK, NICE 
recommends progressively intensive interventions based on degree of overweight 
and obesity and presence of co-morbidity(ies).  
Figure 1 about here 
The initial rate of weight loss in the 1st month as well as the 2nd month also predicts 
weight loss at 4 and 8 years in the Look AHEAD study (panel 4 of figure 1).   Those 
losing <3% at 2 months were 2.5% below baseline at 8 years, those losing 3-6% 
were about 4.5% below baseline at 8 years and those losing >6% were just over 7% 
below baseline on average at 8 years, data which suggests that larger early weight 
losses are beneficial.40     Commercial programs of many types can provide a useful 
strategy for some individuals to lose weight 41.    There are several commercial 
weight loss programmes available, and some individuals may benefit from them. The 
costs and methods of delivering treatment vary which may affect compliance and 
real-world applicability.  These programmes provide on the average about 3% weight 
loss over a year, but long-term compliance is generally poor.   Studies of longer than 
a year are sparse.   A meta-analysis comparing these “named” diets found not 
significant differences between them 42. 
Diets for Weight Loss (Words = 581).    
Several considerations enter into selecting a diet for weight loss.   It must 
have less energy than is required for daily maintenance 29, 43,44 and one to which the 
patient with obesity will adhere and possibly provide other health benefits.  Reducing 
energy by 500 kcal/d below energy requirements or by using a dietary plan which 
has 1200 to 1500 kcal/d for women or 1500 to 1800 kcal/d for men (increased by a 
further 300 kcal/d for each gender if weight exceeds 150 kg) will accomplish the first 
goal.  In addition to reducing calories, some dietary patterns appears to offer other 
health benefits. 45, 46, 47 
There is an entrenched belief that there is a “magic” weight loss diet.  This 
belief has stimulated numerous studies that have focused on different amounts of 
dietary fat, protein or carbohydrate.  These low-fat diets, low-carbohydrate/high-
protein diets, low glycaemic-index diets, balanced deficit diets have been compared 
in many studies and summarized in a few meta-analyses.  One of the largest studies 
with 811 patients who were obese or overweight, the POUNDS Lost study, 
compared diets with 20% or 40% fat and 15% or 25% protein and found no 
difference in weight loss at 6 months or 2 years. 48  A meta-analysis of low 
carbohydrate versus low fat diets was in essential agreement stating that low-
carbohydrate diets are at least as effective as low-fat diets at reducing weight and 
improving metabolic risk factors. 49  A systematic review of evidence from 17 diets 
also found that no one diet was superior.29 Similarly, a meta-analysis of “named” 
diets found no significant difference in weight loss between them.42  Thus the best 
current advice is to provide low energy diets that are likely to be followed by the 
patient and provide health benefits.   
A slightly more favourable picture emerges for the Mediterranean style diet. In 
a meta-analysis of nine studies with 1178 patients Mediterranean style diets were 
associated with a significant decline of body weight and BMI and reductions in 
hemoglobin A1c, fasting plasma glucose, and fasting insulin.50   Along with this effect 
on body weight, one version of this dietary pattern can reduce CVD risk.47  
The jury is still out about low glycaemic index/load diets.  A 5 week 
randomized trial found no significant effect on insulin resistance or markers of CVD 
risk.51   A meta-analysis of 14 studies, however, raised concern. Although C-reactive 
protein and fasting insulin did benefit from the low GI/GL diets, there was a 
significant loss of fat free mass leading to caution in recommending the use of low 
glycaemic index diets for weight loss.52 
Very low-calorie diets (VLCD) or very low-energy diets (VLED), defined as 
having 200 and 800 kcal/day provide a lower energy intake that might result in more 
rapid loss of body fat and weight. Some interesting work has shown that such an 
approach can rapidly normalize blood glucose and other risk factors in people with 
type 2 diabetes.  Systematic reviews, however, 32,53 suggested that although initial 
weight loss is more rapid, weight change after one year or more is not much different 
from comprehensive or multi-component approaches and does not recommend their 
routine use, although they may be considered if rapid weight loss is clinically 
necessary. In their analysis of commercial programs, Gudzune et al found that very-
low-calorie (VLCD) programs, which are usually medically monitored (Health 
Management Resources, Medifast, and OPTIFAST) resulted in at least 4.0% greater 
short-term weight loss than counselling, but some attenuation of effect occurred 
beyond 6 months when this duration of data was available.41 
 
Physical Activity (Word Count = 247) 
Increased physical activity is an essential component of comprehensive 
lifestyle intervention for obesity management.  The recommendations in recent US & 
UK guidelines typically prescribe gradually increasing aerobic physical activity (such 
as brisk walking) to reach a goal of >150 minutes/week (equal to >30 minutes/day, 
for at least 5 days each week).29, 32, 54  This has benefits for general health that are 
independent of weight loss.55  Meta-analysis of trials indicated that this results in an 
additional 1 to 1.5kg weight loss over 12 months over and above dietary intervention 
alone.32, 57 There is evidence that a greater amount physical activity (30-45 minutes 
per day) is required to prevent obesity and that for long-term weight maintenance in 
those who have lost weight, 60-90 minutes per day is required, 29, 56  but this is likely 
to require close supervision as part of an intensive programme, which may not be 
practical or sustainable in many clinical settings.58, 59, 60  However, while this is 
effective in the short term in controlled settings, the activities and their benefits are 
not readily sustained, as was found comparing the 1 and 4 year results in the Look 
AHEAD study.36  The type of physical activity (eg aerobic vs resistance; high 
intensity vs low intensity) does not seem to affect overall weight loss, but as more 
intensive activity produces similar weight loss with a reduced time commitment, they 
might be preferable to some; it would therefore seem appropriate to recommend 
programmes that are acceptable to patients.55, 61   
 
Pharmacotherapy (Words = 1252) 
A recent systematic review and clinical guidance sponsored by the Endocrine 
Society 29 promotes the concept that, for patients with obesity, medicating for chronic 
diseases should be with a weight centric focus.  Many medications in use for 
common chronic diseases produce weight gain, and others are associated with 
weight loss, albeit those medications do not have an obesity indication.  Whenever 
possible, patients with obesity should avoid medications associated with gain and 
use weight neutral medications or those associated with loss (Table 1). 31, 62, 63 
Table 1 (Medications that Produce Weight Gain) 
The indications for adding pharmacotherapy to a weight loss effort are history 
of failure to achieve clinically meaningful weight loss (>5%) and to sustain lost 
weight, for patients who meet regulatory prescribing guidelines (BMI >27 kg/m2 with 
one or more co-morbidities or a BMI >30 kg/m2 with or without associated metabolic 
consequences). 29, 31, 32  
Five medications have been approved in the US for chronic weight 
management, and three of these have also been approved in the EU.  [See Table 2.   
for dosing, mechanism of action and efficacy, safety and tolerability of these drugs.  
The data supporting these tables is derived from the prescribing information labelling 
approved by the US FDA].64, 65, 66, 67, 68, 69 Figure 2 shows the sites of action for these 
medications. 
Figure 2 about here 
Table 2.  Medications Approved in EU and/or US: Mechanism of Action, 
Dosing, Efficacy, Tolerability and Safety 
Several guiding principles should be followed when prescribing drugs for 
weight loss.31  First, effective lifestyle support for weight loss should be provided 
during their use. These medications work to reinforce the patient’s attempts to 
change eating behaviours and produce an energy deficit. Second, the prescriber and 
patient should be familiar with the drug and its potential side effects. Third, unless 
clinically meaningful weight loss occurs after 3 to 4 months, [generally defined as 
more than 4 to 5% in patients without diabetes (In patients with obesity and diabetes 
>3% weight loss can be considered satisfactory)] a new treatment plan should be 
implemented. No one medication is effective in every patient just as not every patient 
is appropriate for every medication.  
Phentermine is a sympathomimetic drug with cardiostimulatory properties. 64 It 
has only been studied in short-term trials and is a controlled substance in the US. It 
has abuse potential (albeit small) and small risk of primary pulmonary hypertension, 
thus making its use for managing a chronic disease less than ideal.  Orlistat is a 
pancreatic lipase inhibitor that blocks absorption of 30% of ingested fat when eating 
a 30% fat diet.70  It is available in most countries world-wide.   Orlistat is among the 
safest drugs in this category 64 and is approved for use in adolescents.71   
Additionally, a study of 4 years duration72 supports its long term safety and efficacy 
and shows that it reduces the development of diabetes mellitus in people with 
prediabetes.  However the drug’s gastrointestinal side effects 65 limit its popularity 
with patients.         
Since 2012, 4 medications have reached the market in the US – lorcaserin, 73, 
74, 75, a combination of phentermine/topiramate ER,76, 77, 78 a combination of 
naltrexone SR/bupropion SR 79, 80, 81, 82 and liraglutide 3.0 mg.83, 84, 85, 86 These drugs 
are required by regulatory agencies in the US and EU to present data on >2500 
patients and to approximate or exceed 5% greater weight loss than placebo  and to 
demonstrate positive effects on a variety of risk factors and disease markers.  All  
agents must show evidence of no increase in cardiovascular risk, which is likely to 
require a cardiovascular outcome trial either before or after marketing..  Further, all 
of these drugs were studied with a suicidality rating scale.87  These medications have 
an indication for “chronic weight management” indicating long-term usage, along with 
diet and physical activity in individuals with BMI >30 kg/m2 or a BMI >27 kg/m2 with 
one or more comorbidities.  They are to be used over the long term, not just to 
produce weight loss, but to sustain lost weight.   
Lorcaserin is a specific serotonin 2c receptor agonist.73  Lorcaserin is 
remarkable for its tolerability and low rate of adverse events.  73, 74, 75   
Echocardiograms performed in phase III studies on more than 5200 subjects found 
no statistically significant increase in FDA defined valvulopathy. 66 The drug should 
not be used with monoamine oxidase inhibitors (MAOIs) because of the risk of 
serotonin syndrome. 66 It has not been studied with SSRIs, SNRIs or other 
serotonergic agents and extreme caution should be used in combining it with those 
agents.66    
           The combination of phentermine and topiramate as in extended release (ER) 
formulation (PHEN/TPM ER) uses lower doses of both (7.5/46 mg at the 
recommended dose) than are usually prescribed when either drug is used as single 
agent. 76, 77, 78 This medication is associated with greater mean weight loss than 
other available medications. Topiramate is associated with fetal toxicity (oral clefts) 88  
and a pregnancy test prior to initiating therapy and monthly thereafter is 
recommended.67  The most common side effects include paresthesias, dizziness, 
dysgeusia, insomnia, constipation and dry mouth.67 A rare side effect of topiramate is 
acute myopia with glaucoma and the drug is contraindicated in glaucoma.67  The 
combination of PHEN/TPM ER is also contraindicated in hyperthyroidism and within 
14 days of treatment with monoamine oxidase inhibitors (MAOIs).67 Other rare 
potential adverse risks include kidney stones (associated with topiramate) and 
increased heart rate (associated with phentermine) in patients susceptible to 
sympathomimetic drugs.67    
The combination of naltrexone SR/bupropion SR was approved in the US in 
2012 and in the EU in 2015.79, 80 81, 82  Bupropion is a mild reuptake inhibitor of 
dopamine and norepinephrine. Naltrexone, an opioid antagonist has minimal effect 
on weight loss on its own.   Naltrexone is thought to block inhibitory influences of 
opioid receptors activated by the β-endorphin released in the hypothalamus that 
stimulates feeding, thus allowing the inhibitory effects of α-melanocyte stimulating 
hormone (α-MSH) to reduce food intake. Naltrexone SR/ bupropion SR can increase 
blood pressure; the combination should only be prescribed to patients with controlled 
hypertension and the patient’s blood pressure should be monitored in the early 
weeks of therapy.68  Despite these signals, absence of increased events in the 
interim analysis of a cardiovascular outcome trial conducted before marketing 
allowed approval.68 Another cardiovascular outcome trial was required post-
marketing.  Tolerability issues, chiefly nausea on initiating the drug mandate a dose 
escalation over four weeks.  All antidepressants in the US are required to carry a 
black box warning of suicidality and the combination’s label includes this.68  
However, there was no signal for suicidality in phase III studies. 78, 79, 80, 81, 83   
Liraglutide is a GLP-1 agonist with a 97% homology to GLP-1 which extends 
its circulating half-life. It has been used for management of diabetes at doses up to 
1.8 mg, given by injection.  It is now approved in the US and EU for chronic weight 
management at a dose of 3.0 mg. 83, 84, 85, 86  Nausea has been one of the principal 
complaints in patients injecting this drug and a slow dose escalation over 5 weeks is 
prescribed.69   There is also a small, but significant increase in heart rate, but blood 
pressure tends to fall.69 GLP-1 agonists are associated with thyroid C cell tumors in 
animals, but this has not been demonstrated with certainty in humans.69  Liraglutide 
should not be prescribed in patients with family or personal history of medullary 
thyroid cancer or multiple endocrine neoplasia.69  Acute pancreatitis, gall bladder 
disease and hypoglycemia in diabetics are safety issues that require managing if 
they occur.   
 Surgical Procedures in the Treatment of Obesity (Word Count = 509) 
Bariatric surgery has rapidly become adopted as a treatment option for severe 
obesity, particularly since the advent of lower risk laparoscopic procedures, with 
nearly half a million procedures performed worldwide in 2013.89  A range of 
procedures are now well-established which result in varying degrees of weight loss;  
each procedure has its own risks and benefits which need to be considered carefully 
with each patient  (Table 3).90 
Table 3 about here 
Longer term studies of outcomes following bariatric surgery have generally 
shown favourable results.  The Swedish Obese Subjects study followed 2000 
patients for up to 20 years after surgery including banded gastroplasty, gastric 
banding and Roux-en-Y gastric bypass performed by open techniques which have 
since been replaced by laparoscopy.  There was a 24% reduction in mortality, mainly 
due to reduced risk of myocardial infarction and cancer (in women), compared to an 
observational control group.91, 92  Many other co-morbidities, such as type 2 diabetes 
and sleep apnoea are also improved, and patients report consistent improvements in 
quality of life.93 
 
Particularly striking and rapid improvements in glucose control have been 
seen in patients with type 2 diabetes, especially following gastric bypass, suggesting 
that part of the metabolic improvement is independent of weight loss.94  Head to 
head randomised controlled trials against medical treatment for type 2 diabetes 
consistently show greater improvements in glucose control and other risk factors in 
the surgical group.95, 96, 97, 99  Observational data also suggest that future risk of 
diabetes-related micro- and macrovascular complications are also reduced.99  This 
has led to the concept of ‘metabolic’ surgery, and recent revision of guidelines and 
recommendations to lower thresholds for considering surgery in people with type 2 
diabetes, particularly of recent onset, to include patients with a BMI between 30 and 
35 kg/m2, 32, 100, 101 and a move away from BMI as the main criterion used to assess 
eligibility for surgery.100 These encouraging data need to be put into the context of 
potential risks and side-effects of surgery, which for some patients can be distressing 
or disabling.  Although mortality is low for modern laparoscopic surgery, re-operation 
rates for surgical complications are significant, particularly for gastric banding (Table 
3).  Some patients find it hard to adapt to the profound changes in the amount and 
type of food they can eat once they have had the procedure and lifelong replacement 
therapy and monitoring is required for nutritional vitamin and mineral deficiencies, 
particularly after malabsorptive surgery.  Dumping syndrome  gastro-oesophageal 
reflux and hypoglycaemia can be very distressing and a challenge to treat.103  
Weight regain can also be a significant problem, and revisional surgery carries 
greater risks and no guarantee of success; 104 there is an increasing focus on 
lifestyle programmes after bariatric surgery to reduce the risk of this occurring. 32 
 
From a clinical perspective it is essential that patients and clinicians 
considering referral for bariatric surgery are fully aware of the risks and benefits; 
good practice might include provision of a detailed education session, attendance at 
patient support groups as well as detailed lifestyle advice and psychological support 
both before and after surgery. 105 
 
Controversies: (words = 529) 
As with other areas of medicine, not all issues have been resolved to 
everyone’s satisfaction.  Below is a list of some of the controversies that are up for 
continuing debate and resolution.   
Should obesity be a strong focus of undergraduate medical education or 
should it be taught primarily at the most graduate level? 106  Weight bias is commonly 
observed among medical students as well as experienced doctors to stigmatize 
patients.107  This stigma might be reduce if the complexities of obesity were 
introduced earlier.  This stigma might also partly explain why obesity is an under-
diagnosed and under-treated condition despite its high prevalence. 108 
Who needs to lose weight and what is the best way to decide?  Is BMI an 
appropriate measure to decide who should lose weight ?109  If not appropriate in 
itself what will improve clinical decision making?  Is the percentage of weight 
reduction  acceptable as a primary endpoint given that several additional benefits not 
requiring weight loss can be of equal clinical relevance? Should a weight- or BMI-
centric approach should be abandoned in favor of a wider array of endpoints such as 
improvements in cardiometabolic variables. Introduction of additional criteria for 
identifying patients at high risk, should be discussed.  
A third controversy revolves around whether there are people who are obese 
and “metabolically healthy” the so-called Metabolic Healthy Obesity or MHO.   
Individuals with metabolically healthy obesity (MHO) may not improve their cardio-
metabolic risk factors significantly after weight loss interventions and may therefore 
not benefit to the same extent as obese patients with metabolic comorbidities. There 
is controversy as to whether individuals labeled as “metabolic-health-obese” are 
really healthy, especially since no general agreement exists on accepted criteria to 
define those with MHO.110, 111 Moreover, there is still controversy as to whether MHO 
can be considered an established phenotype or rather represents a transient stage 
toward ill-health with ageing, behavioural and environmental factors. MHO appears 
to be a relatively transient condition with a considerable percentage of these 
individuals exhibiting similar metabolic derangements to those observed in obese 
metabolically altered patients as time passes.112, 113 Conversely, non-obese 
individuals according to BMI but obese based on body fat distribution exhibit 
elevated  cardiometabolic risk factors 114, 115, and should be identified and treated 
irrespective of BMI. 
 
One of the major uncertainties for patients with obesity is whether current 
pharmacological treatments increase, reduce or are neutral with respect to 
cardiovascular events. This is currently under investigation in the Cardiovascular 
Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects 
With Cardiovascular Risk Factors (The Light Study) (NCT01601704) and Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A 
Long Term Evaluation (LEADER®) (NCT01601704).     
The question of whether obesity should be treated in primary care or by 
specialists with training in obesity is one that will have major impacts on health 
services. A number of studies (NCT00991640, NCT01967797 and NCT01606813) 
are due to report on this problem in the next few years. 
Obesity raises a number of societal controversies. Government taxes on 
“unhealthy” foods has been tried in some countries (Denmark for example) but with 
variable results. Should governments subsidize commercial weight loss programs 
that have proven to be successful?  116 
 
 
Legends: 
Figure 1. Factors that predict weight loss in the Look AHEAD study (Refs 36, 40)  
The results in panels A, B and C indicate the greater weight loss at 1-year 
associated with greater proportion of visits, attended, minutes per week of physical 
activity, and greater meal replacement use.  Black bars indicate the first quartile and 
light gray ones the 4th quartile.  Panel D shows the weight loss at years 4 and 8 by 
percent weight loss at one month (left side) and 2 months (right side).  The tertiles of 
weight ranges are shown below each set of bars. 
  
 
Figure 2. Targets for anti-obesity drugs.  White boxes indicate specific drugs 
located next to the target upon which they are acting. Inside the white 
boxes green names stand for already approved drugs, whereas red 
names represent drugs in phase I-III development. The right hand 
panel summarizes the neurotransmitters and pathways involved in the 
central nervous system in energy homeostasis, while the left hand 
panel represents the mechanisms operative in the periphery. The 
intermediate area represents where the effects of both central and 
peripheral actions converge, namely on the two main components of 
the energy balance equation, i.e. energy intake and expenditure. Note 
that most of the currently approved drugs are working centrally where 
stimulation of the POMC/CART pathway has anorexigenic effects, 
while the NPY/AGRP pathway exerts orexigenic effects. The 
interaction with the multiple receptors present in neurones of the 
hypothalamus determines the balance between orexigenic and 
anorexigenic influences. Most of the drugs currently tested in clinical 
trials are aimed at peripheral systems. Thus, thyroid analogues and 3 
adrenergic agonists induce thermogenesis via activation of brown 
adipose tissue (BAT), thereby increasing energy expenditure. Enzymes 
involved in lipid metabolism such as DGAT, FAS, MetAP2 and NQO1 
are also being targeted. The gut microbiome as well as the regulation 
of bile acids represent further targets to combat obesity. The lipase and 
SGLT2 inhibitors favour energy loss via the gastrointestinal and renal 
elimination of fat and glucose, respectively. Agonism of pancreatic and 
intestinal hormones like amylin and GLP-1 has also been shown to be 
useful for weight loss. 
 
Abbreviations:  DGAT1 = diacylglycerol O-acyltransferase aminotransferase 1; FAS 
= fatty acid synthase; MetAP2 = methionyl aminopeptidase 2; PexRAP inh = 
peroxisomal reductase activating PPAR inhibitor; NQO1 = NAD(P)H 
dehydrogenase:quinone oxidoreductase 1; SGLT2 = sodium-glucose-linked 
transporter 2; inh = inhibitor; BAT = brown adipose tissue; WAT = white adipose 
tissue; GABA = -aminobutyric acid; DA = dopamine; NE = norepinephrine; CB = 
cannabinoid; H = histamine; 5HT = serotonin; ObR = leptin receptor; GHSR = growth 
hormone secretagogue receptor; AGRP = Agouti-related peptide; CART = cocaine 
amphetamine-related transcript; NPY = neuropeptide Y; Y1R = Y1 receptor; Y2R = 
Y2 receptor; Y5R = Y5 receptor; POMC = proopiomelanocortin C; GLP1R = 
glucagon-like peptide 1 receptor; -MSH = -melanocyte-stimulating hormone; 
MCH1R = melanin-concentrating hormone 1 receptor; MC3R = melanocortin 
receptor type 3; MC4R = melanocortin receptor type 4; -OR = -opioid receptor;  
5HT2c = serotonin receptor type 2c. 
 
Appendix figure 1.  The Global Pandemic of Obesity Illustrated by the 
Prevalence of Obesity by Country for Males over 20 Years of Age. (Ref 5).   
 
Appendix figure 2. Relation of body mass index to mortality in pooled data sets with 
over  900,000 people and the effect of specific causes of death Ref 21). All-cause 
mortality versus BMI for each sex in the range 15-50 kg/m2 (excluding the first 5 
years of follow-up)  Relative risks at age 35-89 adjusted for age at risk, smoking and 
study, were multiplied by a common factor (i.e., floated) to make the weighted 
average match the PSC mortality rate at age 35-79 years.  Area of the square is 
inversely proportional to the variance of the long risk.    
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Appendix Table: Common side effects and contraindications and warnings for 
medications used to treat patients who are overweight or obese.  
  
Author Contributions to the Manuscript:  
George Bray was invited to develop the review and invited Dr. Donna Ryan, Dr. 
Gema Frühbeck and Dr. John Wilding to contribute. Bray drafted the initial 
manuscript which was substantially revised by each author. All 4 authors contributed 
to the literature search and to the development of figures and tables. 
The authors identify the following potential conflicts of interest:  Dr. Bray is a 
consultant to Herbalife International and Medifast; a member of the Speakers Bureau 
for Novo Nordisk Pharmaceuticals and Takeda Pharmaceuticals; receives royalties 
from Up-to-Date and Handbook of Obesity; Dr. Frühbeck is a consultant to Novo 
Nordisk Pharmaceuticals; Dr. Ryan is a consultant to Novo Nordisk Pharmaceuticals, 
Takeda Pharmaceuticals, Eisai Pharmaceuticals, Vivus Pharmaceuticals, Janssen 
Pharmaceuticals, Amgen Pharmaceuticals, Real Appeal, Gila Therapeutics, Tulip 
Medical and Scientific Intake and is on the speakers bureau for Novo Nordisk 
Pharmaceuticals, Takeda Pharmaceuticals, Eisai Pharmaceuticals and Vivus 
Pharmaceuticals, and has equity ownership in Scientific Intake; Dr. Wilding received 
grant funding from Novo Nordisk and AstraZeneca, and is a consultant to Novo 
Nordisk, Janssen Pharmaceuticals, AstraZeneca Pharmaceuticals, Boehringer 
Ingelheim Pharmaceuticals, and  Pfizer Pharmaceuticals.  
 
  
References: 
1. World Health Organization, WHO Obesity and Overweight Fact Sheet No 311, 
March 2013 available at http://who.ubt.neduacebter.factsheet.fs311/en. 
2.  “Overweight and Obesity”  www.cdc.gov/obesity/adult/defining. Html: accessed 
January 7, 2015 
3.  Statistics on Obesity, Physical Activity and Diet: England 2015. Health and Social 
Care Information Centre; published March 2015. 
http://www.hscic.gov.uk/catalogue/PUB16988/obes-phys-acti-diet-eng-2015.pdf 
4.  European Statistics World Health Organization Europe, Data and Statistics 
http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-
and-statistics 
5.  Ng M, Fleming T, Robinson M, et al.  Global regional, and national prevalence of 
overweight and obesity in children and adults during 1980-2013: a systematic 
analysis of the Global burden of Disease Study 2013.  Lancet 2014;384:766-781. 
6. Scully T. Public health: Society at large. Nature. 2014;508:S50-1. 
7. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y.  
Healthy percentage body fat ranges: an approach to developing guidelines based on 
body mass index. Am J Clin Nutr 2000;72:694-701 
8.  Romero-Corral A, Lopez-Jimenez F, Sierra-Johnson J, Somes VK.  Differentiating 
between body fat and lean mass – how should we measure obesity?. Nat Clin Pract 
Endocrinol Metabol 2008;4:322-323. 
9. Ashwell MA, Waist-to-height ratio is a better screening tool than waist 
circumference and BMI for adult cardiometabolic risk factors: systematic review and 
meta-analysis.  Obes Rev 2012;13:275-286 
10. Cerhan JR, Moore SC, Jacobs EJ, et al.  A pooled analysis of waist 
circumference and mortality in 650,000 adults.  Mayo Clin Proc 2014;89:335-345. 
11. Staiano AE, Bouchard C, Katzmarzyk PT. BMI-specific waist circumference 
thresholds to discriminate elevated cardiometabolic risk in White and African 
American adults. Obes Facts 2013;6:317-24. 
12.  Tsai AG, Williamson DF, Glick HA.  Direct medical cost of overweight and 
obesity in the USA: a quantative systematic review. Obes Rev 2011;12:50-61. 
13.  Finkelstein EA, Graham WC, Malhotra R. Lifetime direct medical costs of 
childhood obesity.  Pediatrics 2014;133:854-862. 
14.  Bray GA.  Diabetes and Obesity – Time bombs to be defused.  Diab Care 
2015;38:1–3  
15.  Cawley J, Meyerhoefer C.  The medical care costs of obesity: an instrumental 
variable approach. J Health Econ 2012;31:218-230. 
16.  Wang YC, McPerson K, Marsh T, Gortmaker SL, Brown M.  Health and 
economic burden of the projected obesity trends in the USA and the UK.  Lancet 
2011;378:815-825. 
17.  Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz 
W.  Obesity and severe obesity forecasts through 2030.  Am J Prev Med 
2012;42:563-570. 
18.  Loeppke R, Taitel M, Haufle V, Parry T, Kessler RC, Jinnett K.  Health and 
productivity as a business strategy: a multiemployer study.  J Occup Environ Med 
2009;51:411-428. 
19.  Keith SW, Redden DT, Katzmarzyk PT, et al. Putative contributors to the secular 
increase in obesity: exploring the roads less traveled. Int J Obes 2006;30:1585-1594. 
20.  Janesick AS, Shioda T, Blumberg B. Transgenerational inheritance of prenatal 
obesogen exposure. Mol Cell Endocrinol 2014;398:31-5. 
21. Prospective Studies Collaboration.  (Whitlock G, Lewington S, Sherliker P, 
Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R.  Body-mass index 
and cause-specific mortality in 900,000 adults: collaborative analyses of 57 
prospective studies.  Lancet 2009;373:1083-1096. 
22.  Li C, Ford ES, Zhao G, Croft JB, Balluz LS, Mokdad AH.  Prevalence of self-
reported clinically diagnosed sleep apnea according to obesity status in men and 
women: National Health and Nutrition Examination Survey, 2005-2006.  Prev Med 
2010;51:18-23. 
23.  Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis 
RJ, Moore SC, Tobias GS, Anton-Sulver H, Greeman LB, Geeson WL, Clipp SL, 
English DR, Folsome AR, Freedman DM, Giles G, Hakansson N, Henderson KD, 
Hoffman-Bolton, J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, 
Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, 
Willett WC, Thun MJ.  Body-mass index and mortality among 1.46 million white 
adults.  NEJM 2010;363:2211-2219. 
24.  Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting 
from altered body weight.  N Engl J Med. 1995;332(10):621-628. 
26. Bray GA.  Prevention of obesity IN:  De Groot LJ, Beck-Peccoz P, Chrousos G, 
Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, 
Singer F, Vinik A, Weickert MO (EDS).  Endotext [Internet].  South Dartmouth (MA):  
MDText.com, Inc.; 2000- 2012;1-28. 
27. Wang Y, Wu Y, Wilson RF, Bleich S, Cheskin L, Weston C, Showell N, Fawole 
O, Lau B, Segal J. Childhood Obesity Prevention Programs: Comparative 
Effectiveness Review and Meta-Analysis. Comparative Effectiveness Review No. 
115. (Prepared by the Johns Hopkins University Evidence-based Practice Center 
under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-EHC081-EF. 
Rockville, MD: Agency for Healthcare Research and Quality; June 2013. 
www.effectivehealthcare.ahrq.gov/reports/final.cfm. 
28. Sturm R, An R.  Obesity and economic environments.  CA Cancer J Clin 
2014;64:337-350. 
29. Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing 
overweight and obesity in adults. Obesity 2014;22(S2):S1-S410. 
 
30.  AACE Advanced framework for a new diagnosis of obesity as a chronic disease. 
Available at https://www.aace.com/files/2014-advanced-framework-for-a-new-
diagnosis-of-obesity-as-a-chronic-disease.pdf.  Accessed January 15, 2015. 
31.  Apovian CM, Aronne LJ, Bessesen DH et al.  Pharmacologic Management of 
obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 
2015 doi:10.1210/jc.2014-3415. 
32. National Institute for Health and Clinical Excellence: Guidance. Obesity: 
Identification, Assessment and Management of Overweight and Obesity in Children, 
Young People and Adults: Partial Update of CG43. National Clinical Guideline 
Centre (UK). London: National Institute for Health and Care Excellence (UK); 2014 
Nov.6 
33. Yumuk V, Frühbeck G, Oppert JM, Woodward E, Toplak H. An EASO position 
statement on multidisciplinary obesity management in adults.Obes Facts 
2014;7(2):96-101. 
34. Frühbeck G, Toplak H, Woodward E, Halford JC, Yumuk V; European 
Association for the Study of Obesity. Need for a paradigm shift in adult overweight 
and obesity management - an EASO position statement on a pressing public health, 
clinical and scientific challenge in Europe.Obes Facts. 2014;7(6):408-16.  
35. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee 
IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, 
Svetkey LP, Wadden TA, Yanovski SZ; American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines.  2013 AHA/ACC guideline on 
lifestyle management to reduce cardiovascular risk: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines.  J Am 
Coll Cardiol. 2014 Jul 1;63(25 Pt B):2960-84.  
36. The Look AHEAD Research Group (Wadden TA, Bantle JP, Blackburn GL, et al),  
Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD 
Study. Obesity 2014; 22, 5–13.  
37. Diabetes Prevention Program Research Group (Knowler WC, Fowler SE, 
Hamman RF, et al) 10-year follow-up of diabetes incidence and weight loss in the 
Diabetes Prevention Program Outcomes Study. Lancet 2009; 374(9702): 1677-1686. 
38. LeFevre, M. L. Behavioral counseling to promote a healthful diet and physical 
activity for cardiovascular disease prevention in adults with cardiovascular risk 
factors: U.S. preventive services task force recommendation statement. Annals of 
Internal Medicine 2014;161(8): 587-593. 
39. Decision Memo for Intensive Behavioral Therapy for Obesity (CAG- 00423N) 
http://www.cms.gov/medicare-coverage-
database/shared/handlers/highwire.ashx?url=http://www.cms.gov/medicare-
coverage-database/details/nca-decision-memo.aspx  Accessed January 15, 2015. 
40. Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, Jeffery R, Nelson JA, 
Pi-Sunyer X, Smith-West D, Wing RR the Look AHEAD Research Group Obesity 
2015;23:1353-1356 
41. Gudzune KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, Lee 
CJ, Bleich SN, Clark JM.  Efficacy of commercial weight-loss programs: an updated 
systematic review.  Ann Intern Med. 2015 Apr 7;162(7):501-12. 
42. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among 
named diet programs in overweight and obese adults: a meta-analysis.  JAMA. 
2014; Sep 3;312(9):923-33.  
43. Thomas DM, Weedermann M, Fuemmeler BF, et al. Dynamic model predicting 
overweight, obesity and extreme obesity prevalence trends.  Obesity 2014;22:590-
597. 
44. Hall KD, Sacks F, Chandramohan D, et al.  Quantification of the effect of energy 
imbalance on body weight Lancet 2011;378:826-837. 
45. Siervo M, Lara J, Chowdhury S, Ashor A, Oggioni C, Mathers JC.  Systematic 
Review with Meta-Analysis.  Effects of the Dietary Approach to Stop Hypertension 
(DASH) diet on. cardiovascular risk factors: a systematic review and meta-analysis.  
British Journal of Nutrition 2015;113: 1–15. 
46. Appel LJ, Moore TJ, Obarzanek E, et al. (1997). A clinical trial of the effects of 
dietary patterns on blood pressure. DASH Collaborative Research Group. New Engl 
J Med 1997;336:1117-1124. 
47. Estruch R, Rios E, Salas-Salvedo J, et al. Primary prevention of cardiovascular 
disease with a Mediterranean diet. New England Journal of Medicine 2013;368(14): 
1279-1290. 
48. Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with 
different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360(9): 
859-873. 
49. Hu T, Mills KT, Yao L, Demanelis K, Eloustaz M, Yancy WS Jr, Kelly TN, He J, 
Bazzano LA. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk 
factors: a meta-analysis of randomized controlled clinical trials.  Am J Epidemiol. 
2012 Oct 1;176 Suppl 7:S44-54. 
50. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, Yu X.  Effects of Mediterranean-style 
diet on glycemic control, weight loss and cardiovascular risk factors among type 2 
diabetes individuals: a meta-analysis.  Eur J Clin Nutr. 2014 Nov 5. doi: 
10.1038/ejcn.2014.243.  
51. Sacks FM, Carey BJ, Anderson CA, et al.  Effects of high vs low glycemic index 
on dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: 
the OmniCarb randomized clinical trial.  JAMA 2014;312:2531-2541 
52. Schwingshackl L, Hoffmann G.  Long-term effects of low glycemic index/load vs. 
high glycemic index/load diets on parameters of obesity and obesity-associated 
risks: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2013 
Aug;23(8):699-706.  
53. Tsai AG, Wadden TM.  The evolution of very-low-calorie diets: an update and 
meta-analysis. Obesity. 2006;14:1283–1293 
54. Jakicic  JM, Egan CM, Fabricatore AN, et al; Look AHEAD Research Group. 
Four-year change in cardiorespiratory fitness and influence on glycemic control in 
adults with type 2 diabetes in a randomized trial: the Look AHEAD Trial. Diab Care.  
2013 May;36(5):1297-303. 
55. SIGN 115 Management of Obesity http://www.sign.ac.uk/pdf/sign115.pdf 
accessed 21 August 2015 
 
56. Slentz CA, Houmard JA, Kraus WE. Exercise, abdominal obesity, skeletal 
muscle, and metabolic risk: evidence for a dose response. Obesity (Silver Spring). 
2009;17 (Suppl 3):S27-33. 
 
 
57. Wu T, Gao, X, Chen M, et al. Long-term effectiveness of diet-plus-exercise 
interventions vs. diet-only interventions for weight loss: a meta-analysis  
Obes Rev  2009;10: 313-323  
 
58. McTiernan A, Sorensen B, Irwin ML, et al. Exercise effect on weight and body fat 
in men and women  Obesity   2007;15:1496-1512  
59. Jakicic JM, Marcus BH, Gallagher, KI, Napolitano M, Lang W. Effect of exercise 
duration and intensity on weight loss in overweight, sedentary women: a randomized 
trial.  JAMA 2003;290:1323-1330  
60. Jakicic, JM; Marcus, BH ; Lang, W ; Janney, C.  Effect of exercise on 24-month 
weight loss maintenance in overweight women Arch Intern Med 168: 1550-1559  
 
61. Ross R, Hudson, R Stotz, PJ, et al, Effects of Exercise Amount and Intensity on 
Abdominal Obesity and Glucose Tolerance in Obese Adults   Ann Intern 
Med  2015;162:325-34.  
 
62. Leslie WS, Hankey CR, Lean ME.  Weight gain as an adverse effect of some 
commonly prescribed drugs: a systematic review.  QJM. 2007 Jul;100(7):395-404.    
63.  Blumenthal SR, Castro VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, 
Weilburg JB, Erb JL, Churchill SE5, Kohane IS6, Smoller JW7, Perlis RH1. An 
electronic health records study of long-term weight gain following antidepressant 
use. JAMA Psychiatry. 2014 Aug;71(8):889-96. 
64. Adipex-P (phentermine) prescribing information.  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/088023s037lbl.pdf. 
Accessed February 22, 2015 
65. Xenical (orlistat) prescribing information. 
http://www.gene.com/download/pdf/xenical_prescribing.pdf.  Accessed February 22, 
2015, 
66. Belviq (lorcaserin) prescribing information. 
https://www.belviq.com/pdf/Belviq_Prescribing_information.pdf.  Accessed February 
22, 2015. 
67. Qsymia (phentermine/topiramate ER) prescribing information.  
https://qsymia.com/pdf/prescribing-information.pdf.  Accessed February 22, 2015. 
68. Contrave (naltrexone SR/bupropion SR) prescribing information. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. 
Accessed February 22, 2015. 
69. Saxenda (liraglutide 3.0 mg) prescribing information.  http://novo-
pi.nnittest.com/saxenda.pdf.  Accessed January 18, 2015. 
70. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, 
Krempf M.  Randomised placebo-controlled trial of orlistat for weight loss and 
prevention of weight regain in obese patients. European Multicentre Orlistat Study 
Group.  Lancet. 1998 Jul 18;352(9123):167-72. 
 
71. Chanoine JP, Jampl S, Jensen C, Boldin M, Hauptman J.  Effect of Orlistat on 
body weight and body composition in obese adolescents: a randomized controlled 
trial.  JAMA 2005;293:2873-2883. 
72. Torgerson, J. S., Hauptman, J., Boldrin, M. N., and Sjöström, L. XENical in the 
Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of 
orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in 
obese patients. Diabetes care 2004;27(1):155-161. 
73. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays 
H, Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and 
Obesity Management (BLOOM) Study Group.  Multicenter, placebo-controlled trial of 
lorcaserin for weight management.  N Engl J Med. 2010 Jul 15;363(3):245-56. 
74. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, 
Anderson CM, Shanahan WR.  Randomized placebo-controlled clinical trial of 
lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.  Obesity 
(Silver Spring). 2012 Jul;20(7):1426-36. 
75. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, 
Anderson CM; BLOSSOM Clinical Trial Group.  A one-year randomized trial of 
lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.  J Clin 
Endocrinol Metab. 2011 Oct;96(10):3067-77.  
76. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day 
WW  Effects of low-dose, controlled-release, phentermine plus topiramate 
combination on weight and associated comorbidities in overweight and obese adults 
(CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 
16;377(9774):1341-52.  
77. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM.  
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-
release in obese adults.  Obesity (Silver Spring). 2013 Nov;21(11):2163-71. 
78.  Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, 
Tam PY, Troupin B, Day WW.  Controlled-release phentermine/topiramate in 
severely obese adults: a randomized controlled trial (EQUIP).  Obesity (Silver 
Spring). 2012 Feb;20(2):330-42.  
79. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich 
E; COR-II Study Group.  A randomized, phase 3 trial of naltrexone SR/bupropion SR 
on weight and obesity-related risk factors (COR-II).  Obesity (Silver Spring). 2013 
May;21(5):935-43. 
80. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen 
P, Fujioka K; COR-Diabetes Study Group.  Effects of naltrexone sustained-
release/bupropion sustained-release combination therapy on body weight and 
glycaemic parameters in overweight and obese patients with type 2 diabetes.  
Diabetes Care. 2013 Dec;36(12):4022-9. 
81. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, 
Kim DD, Dunayevich E; COR-I Study Group.  Effect of naltrexone plus bupropion on 
weight loss in overweight and obese adults (COR-I): a multicentre, randomised, 
double-blind, placebo-controlled, phase 3 trial.  Lancet. 2010 Aug 21;376(9741):595-
605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 
2010 Aug 21;376(9741):594. Lancet. 2010 Oct 23;376(9750):1392.  
82. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-
Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E  Weight loss 
with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior 
modification: the COR-BMOD trial.  Obesity (Silver Spring). 2011 Jan;19(1):110-20. 
doi: 10.1038/oby.2010.147. Epub 2010 Jun 17. 
83. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, 
Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 
Investigators.  Safety, tolerability and sustained weight loss over 2 years with the 
once-daily human GLP-1 analog, liraglutide.  Int J Obes (Lond). 2012 Jun;36(6):843-
54. 
 
84. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; 
NN8022-1923 Investigators.   Weight maintenance and additional weight loss with 
liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance 
randomized study.  Int J Obes (Lond). 2013 Nov;37(11):1443-51.  
 
85. Pi-Sunyer FX, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, 
le Roux CW, Violante OR, Jensen CB, Wilding JP.   A randomized, controlled trial of 
3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015;373:11–22. 
86. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen 
AH, Jensen CB, DeFronzo RA; NN8022-1922 Study Group.  Efficacy of Liraglutide 
for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes 
Randomized Clinical Trial.  JAMA. 2015 Aug 18;314(7):687-99.  
87. Giddens JM, Sheehan KH, Sheehan DV.  The Columbia Suicidality severity 
rating scale (C-SSRS): has the gold standard become a liability? Innov Clin Neurosci 
2014;11:66-80.  
 
88. Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, 
Hernandez-Diaz S; National Birth Defects Prevention Study.  Use of topiramate in 
pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012 Nov;207(5):405.e1-7. 
doi: 10.1016/j.ajog.2012.07.008.  
89. Angrisani L, Santonicola A, Lovino P, Formisano G, Buchwald H, Scopinaro N.. 
Bariatric Surgery Worldwide 2013. Obes Surg. 2015 Oct;25(10):1822-32.  
 
90. Jeffrey I. Mechanick et al Clinical Practice Guidelines for the Perioperative 
Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient— 
2013 Update Endocrine Practice Vol 19 No. 2 March/April 2013 
 
91. Sjostrom L, Narbro K, Sjostrom CD, et al. Effect of bariatric surgery on mortality 
in Swedish obese subjects. N Engl J Med; 2007;357:741-772. 
 
92. Sjostrom L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term 
cardiovascular events. JAMA 2012; 307: 56–65. 
 
93. Sjostrom, L. Review of key results from the Swedish Obese Subjects (SOS trial – 
a prospective controlled intervention study of bariatric surgery. J Intern Med 
2013;273:219-234. 
 
94. Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 
diabetes.  Lancet. 2012 Jun 16;379(9833):2300-11. 
 
95. Kashyap, SR, et al. Metabolic effects of bariatric surgery in patients with 
moderate obesity and type 2 diabetes: analysis of a randomized control trial 
comparing surgery with intensive medical treatment. Diab Care, 2013;36:2175–2182. 
 
96. Ikramuddin, S. et al. Roux-en-Y gastric bypass vs intensive medical 
management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the 
Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240–2249. 
 
97. Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for 
diabetes—3-year outcomes. N. Engl. J. Med. 2014;370:2002–2013. 
 
98. Mingrone G, , Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, 
Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus 
conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-
up of an open-label, single-centre, randomised controlled trial. Lancet 2015; 
386:964-73. 
 
99. Sjostrom Lars, Peltonen M, Jacobson P, et al.  Association of Bariatric Surgery 
With Long-term Remission of Type 2 Diabetes and With Microvascular and 
Macrovascular Complications JAMA  2014;311:2297-2304    
 
100. Frühbeck. Bariatric and metabolic surgery: a shift in eligibility and success 
criteria. Nat Rev Endocrinol. 2015 Aug;11(8):465-77.  
 
101. Fried M, et al. Interdisciplinary European guidelines on metabolic and bariatric 
surgery. Obes. Surg. 2014;24:42–55. 
 
102. Chang, SH, et al. The effectiveness and risks of bariatric surgery: an updated 
systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149:275–287. 
 
103. Tack, J. Deloose, E. Complications of bariatric surgery: dumping syndrome, 
reflux and vitamin deficiencies. Best Pract. Res. Clin. Gastroenterol. 2014;28:741–
749. 
 
104. Brethauer SA, Kothari S, Sudan R, Williams B, English WJ, Brengman M, et al.  
Systematic review on reoperative bariatric surgery American Society for Metabolic 
and Bariatric Surgery Revision Task Force.  Surg Obes Relat Dis. 2014 Sep-
Oct;10(5):952-72.  
 
105. Stegenga H, Haines A, Jones K, Wilding J, on behalf of the Obesity Guideline 
Development Group (GDG) Identification, assessment and management of 
overweight and obesity: Summary of NICE guidance British Medical Journal 2014 
349-g6608 doi 10.11.36/bmj.g6608 
 
106. Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. 
Management of obesity: improvement of health-care training and systems for 
prevention and care. Lancet 2015;385:2521-33. 
107 Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M.  
Impact of weight bias and stigma on quality of care and outcomes for patients with 
obesity.  Obes Rev. 2015 Apr;16(4):319-26.  
108.Frühbeck G. Obesity. Screening for the evident in obesity. Nat Rev Endocrinol 
2012; 8:570-572. 
109. Blundell JE, Dulloo AG, Salvador J, Frühbeck G. Beyond BMI – Phenotyping 
the obesities. Obes Facts 2014;7:322-328. 
110. Ahima RS, Lazar MA. Physiology. The health risk of obesity--better metrics 
imperative. Science 2013; 341:856-8. 
111. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and 
obesity benign conditions?: a systematic review and meta-analysis. Annals of 
Internal Medicine 2013;159:758-69. 
112. Chang Y. et al. Impact of BMI on the incidence of metabolic abnormalities in 
metabolically healthy men. Int J Obes (Lond) 2012; 36:1187-94. 
113.Gómez-Ambrosi J. et al. Increased cardiometabolic risk factors and 
inflammation in adipose tissue in obese subjects classified as metabolically healthy. 
Diabetes Care 2014;37: 2813-21. 
 
114. Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Vila N, 
Ibañez P, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J, Frühbeck G. Body 
mass index classification misses subjects with increased cardiometabolic risk factors 
related to elevated adiposity.  Int J Obes 2012;36:286-294. 
115. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the 
obesity paradox. Nat Rev Endocrinol 2015;11(1):55-62. 
116. Thow AM, Downs S, Jan S.  A systematic review of the effectiveness of food 
taxes and subsidies to improve diets: understanding the recent evidence.  Nutr Rev. 
2014 Sep;72(9):551-65.  
 
 
 
Lancet 2015.09.04_Collated_Track Edits 
 
Management of Obesity 
 
George A. Bray1, Gema Frühbeck 2, Donna H. Ryan1 and John PH Wilding3 
 
 
 
1.  Pennington Biomedical Research Center/LSU, Baton Rouge, Louisiana 
2.  Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 
University of Navarra, CIBEROBN, IdiSNA, Spain 
3.  Department of Medicine (Obesity) University of Liverpool, Liverpool, United 
Kingdom 
 
Running Title:  Management of Obesity 
 
Preparation of this paper was supported in part by Fondo de Investigación Sanitaria-
FEDER (FIS PI12/00515) from the Spanish Instituto de Salud Carlos III 
 
 
Word Count: Fast Facts 424;  Main Text 3601;  Controversies 529; Total 4544 
3 Tables, 1 Supplemental Table, 24 Figures in text, 2 figures in appendix and 1166 
References 
 
Key Words:  obesity, obesity treatment, obesity prevention, lifestyle intervention, 
diets for weight loss, physical activity for weight loss, medications for weight loss, 
obesity pharmacotherapy, bariatric surgery,  
 
 
Contact Information: 
 
George A. Bray MD 
Pennington Biomedical Research Center/LSU 
Baton Rouge, Louisiana 70808 
Telephone: (225) 763-3176 
e-mail:  brayga@pbrc.edu 
 
 
 
 
 
  
*Manuscript with revisions highlighted
 Fast Facts (abbreviated) [Words = 424] 
Definition:  Obesity is multifactorial, resulting from genetic, epigenetic, physiological, 
behavioural, sociocultural and environmental influences which produce an imbalance 
between energy intake and expenditure over an extended time period. 
Etiology:  Obesity occurs in genetically susceptible individuals under a variety of 
environmental influences.   
Natural history:  Physiologic processes resist weight loss and produce a “settled” 
weight within a given environment.  Weight loss produces metabolic adaptation 
(lower energy expenditure) and alterations in appetite signals that promote food 
intake.  Persons with obesity struggle to lose weight and regain is common. 
Prevention:  The environment of developed countries is obesogenic.  Environmental 
change is the responsibility of societies.  For individuals with obesity and no 
associated health risk, advise self-help approaches.  
Iatrogenic weight gain: Many medications have been associated with weight gain 
(insulin, sulfonylureas, antidepressants, antipsychotics and others).  For patients at-
risk, avoid them, or prescribe weight neutral alternatives. 
In medical practices, weight management is indicated for individuals with BMI 
>30kg/m2 or >25kg/m2 with an obesity associated comorbidity, including 
increased waist circumference. 
Lifestyle Change: For many patients, changing behaviours requires skill training 
and use of behavioural tools (self-monitoring of food intake, physical activity and 
body weight; environmental control; contingency planning). 
Diet:  Many diets have been shown to produce and sustain weight loss, if they are 
followed.  There is no magic diet.  Choose a diet that the patient will follow and which 
has health benefits.   
Physical Activity:  Give a specific prescription describing the frequency, intensity, 
time and type. For weight loss, recommend minimum goal of 150 min/week.  For 
prevention and maintenance, recommend 250-300 minutes per week is 
recommended.  
Medicating for weight loss is indicated for individuals with BMI >30kg/m2 or 
>27kg/m2 with an obesity associated comorbidity.  Medications approved in 
the US/EU are orlistat, naltrexone/ bupropion and liraglutide.  In the US, 
lorcaserin and phentermine/topiramate are also available.   Use the following 
principles: 
• Medications work by enhancing adherence to diet. 
• Lifestyle is the foundation.  Don’t prescribe medications alone. 
• All medications have different safety profiles that must be matched to the 
patient’s profile. 
• Every medication will not work in every patient.  Stop the medication and try 
another if 4-5% weight loss does not occur in 3-4 months [In obese diabetic 
patients >3% weight loss can be considered satisfactory]. 
• Use medications long term to sustain lost weight. 
 
Surgical management is indicated for individuals with BMI >40kg/m2 or 
>35kg/m2 with an obesity associated comorbidity.  The three most common 
procedures are gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass.   
These procedures have been shown to produce remarkable health improvement and 
to reduce mortality.  Life-long care is indicated to address nutritional needs long-
term.  
 
 
Search strategy and selection criteria 
A search for original articles and reviews published between January 1990 and 
August 2015 focusing on obesity management was performed in PubMed and 
MEDLINE using the following search terms (or combination of terms): “obesity”, 
“weight loss”, “management”, “treatment”, “guidelines”, “recommendations”, “costs”, 
“outcomes”, “comorbidity or comorbidities”, “body composition”, “life-style 
intervention”, “physical activity”, “exercise”,  “pharmacotherapy”, “medication”, “anti-
obesity drugs”, “bariatric surgery” and “metabolic surgery”. Only English-language, 
full-text articles were included. Very recent references from September 2015 were 
also identified and selected. Articles in journals with explicit policies governing 
conflicts-of-interest, and stringent peer-review processes were favoured. Data from 
larger replicated studies with longer periods of observation when possible were 
systematically chosen to be presented. More weight was given to randomized 
controlled trials, prospective case–control studies, meta-analyses and systematic 
reviews. 
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Background/Introduction: (Word Count = 376) 
Over the past 50 years obesity has become an international public health 
problem that impacts the quality of life, increases the risk of illness and raises health 
care costs in countries in all parts of the world (Appendix Figure 1) (1-6).   
Appendix Figure 1 Worldwide prevalence of Obesity in men 
Measurement of obesity in these surveys is done with the body mass index (BMI), 
[wt(kg)/Ht(m2)]  which has a modestly good correlation with body fat  (7).  The BMI 
has the advantage of simplicity in epidemiological studies, but it has deficiencies 
since it does not separate fat from lean body mass (8). Thus, BMI should be 
considered a screening measurement rather than a diagnostic tool.  Additional 
measurements are needed to complement the BMI and should include waist 
circumference (or Waist/Height ratio) (9, 10). Both variables are strong predictors of 
health risk (9, 10).  Ethnic differences in waist circumference need to be considered 
in its clinical use (11).  In addition to measures of central adiposity it is desirable to 
measure blood pressure, glucose and lipids (HDL-cholesterolC and triglycerides).  
Obesity is expensive (12, 13) and along with diabetes is a disease that needs 
to be “defused” (14).  Medical costs rise progressively as BMI increases (15) and are 
expected to continue to rise in the next 15 years (16 17).  Obesity is second only to 
depression in its cost to employers (18). 
Obesity has a multifactorial nature resulting from genetic, epigenetic, 
physiological, behavioural, sociocultural and environmental influences that lead to an 
imbalance between energy intake and expenditure over an extended time period. 
Recently, the importance of less sleep, endocrine disruptors – such as some 
chemicals in food packaging and foods – increased time in climate controlled areas, 
cessation of smoking, weight gain that is associated with some medications 
(described in more detail later), older parental age at birth as well as intrauterine and 
intergenerational effects have been highlighted as contributors to the obesity 
epidemic.19, 20  
 Obesity shortens life span (21) and impacts the function of many organ 
systems (22). ( Appendix Figure 2).  (21, 23)  This mortality results from several 
diseases that are associated with obesity, including diabetes, chronic kidney 
disease, gastro-intestinal disease and cardiovascular disease.  
Appendix Figure 2 Mortality versus BMI 
 Body weight is defended, meaning that maintaining weight loss is often 
difficult or unsuccessful (24).   
Management of the Patient with Obesity (Word count = 171) 
 The rising prevalence of obesity worldwide cries out for preventive strategies 
to defuse the future health and economic costs of this problem. Economic and 
technological changes in the environment have driven the obesity epidemic 
(28Sturm 2014), and many studies have tested strategies in schools, in work-sites 
and in the community that might prevent progression of BMI, but so far, these efforts 
have had limited impact 26, 27 and the evidence for effective economic policies to 
prevent obesity remains limited. 28   
When prevention fails, as it will for many people, treatment is indicated.   To 
guide health care professionals in treating the problem effectively a number of 
guidelines have been developed both in the US, 29, 30, 31  in the UK 32 and in 
Europe.33, 34   We will use these guidelines as the basis for outlining therapy for 
obesity which can include lifestyle changes, dietary modification, increased physical 
activity, the use of medications and in some cases the recommendation for surgery.  
Lifestyle Changes (Word Count = 485):   
The cornerstone for treatment of the patient with obesity in the US, UK and 
Europe is a Comprehensive, or Multi-component Lifestyle Intervention. 29, 30, 32, 35    
The term comprehensive refers to simultaneous implementation of three strategies: 
lifestyle or behavioural training, dietary change to reduce energy intake, and an 
increase in physical activity.  The evidence supporting the efficacy of lifestyle 
intervention or behavioural modification is supported, in part, by data  from 2 large 
randomized clinical trials: the Look AHEAD 36 and the Diabetes Prevention Program. 
37   Three variables, including number of behavioural sessions attended, number of 
meal replacements used and the weekly minutes of physical activity all predicted 
weight loss at 1, 4, and 8 years  in the Look AHEAD study and these are 
summarized for the 8 year data in 3 of the 4 panels in Figure 13.  A systematic 
review of evidence showed that if these components are delivered in at least 14 
face-to-face (group or individual) sessions over six months with treatment continuing 
to one year, average observed weight loss is 8 kg. 29  While this may seem modest, 
it translates into clinically significant improvements in blood pressure, triglycerides, 
HDL cholesterol, measures of glycaemic control and reduction in risk for progression 
to type 2 diabetes. 29    Based on these and other findings, the US Preventive 
Services Task Force 38 has recommended that obese individuals with cardiovascular 
disease (CVD) risk factors should be referred for lifestyle treatment and the US 
Center for Medicare and Medicaid Services promoted policies to reimburse providers 
for intensive behavioural therapy for the patient with obesity. 39   In the UK, NICE 
recommends progressively intensive interventions based on degree of overweight 
and obesity and presence of co-morbidity(ies).  
Figure 13 about here 
The initial rate of weight loss in the 1st month as well as the 2nd month also predicts 
weight loss at 4 and 8 years in the Look AHEAD study (panel 4 of figure 13).   
Those losing <3% at 2 months were 2.5% below baseline at 8 years, those losing 3-
6% were about 4.5% below baseline at 8 years and those losing >6% were just over 
7% below baseline on average at 8 years, data which suggests that larger early 
weight losses are beneficial.40     Commercial programs of many types can provide a 
useful strategy for some individuals to lose weight 41.  In a meta-analysis of 
commercial programs in the US,  found that at 12 months Weight Watchers 
participants achieved at least 2.6% more weight loss than the control/education 
group; the Jenny Craig program weight loss was at least 4.9% greater at 12 months 
than in the control/education and counselling group; the Atkins program resulted in 
0.1% to 2.9% greater weight loss at 12 months than counselling; and the 
Nutrisystem weight loss program was at least 3.8% greater at 3 months than the 
control/education and counseling control groups. 41  There are several commercial 
weight loss programmes available, and some individuals may benefit from them. The 
costs and methods of delivering treatment vary which may affect compliance and 
real-world applicability.  These programmes provide on the average about 3% weight 
loss over a year, but long-term compliance is generally poor.   Studies of longer than 
a year are sparse.   A meta-analysis comparing these “named” diets found not 
significant differences between them 42. 
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Diets for Weight Loss (Words = 582).    
Several considerations enter into selecting a diet for weight loss.   It must 
have less energy than is required for daily maintenance 29, 43,44 and one to which the 
patient with obesity will adhere and possibly provide other health benefits.  Reducing 
energy by 500 kcal/d below energy requirements or by using a dietary plan which 
has 1200 to 1500 kcal/d for women or 1500 to 1800 kcal/d for men (increased by a 
further 300 kcal/d for each gender if weight exceeds 150 kg) will accomplish the first 
goal.  In addition to reducing calories, some dietary patterns appears to offer other 
health benefits. 45, 46, 47 
There is an entrenched belief that there is a “magic” weight loss diet.  This 
belief has stimulated numerous studies that have focused on different amounts of 
dietary fat, protein or carbohydrate.  These low-fat diets, low-carbohydrate/high-
protein diets, low glycaemic-index diets, balanced deficit diets have been compared 
in many studies and summarized in a few meta-analyses.  One of the largest studies 
with 811 patients who were obese or overweight, the POUNDS Lost study, 
compared diets with 20% or 40% fat and 15% or 25% protein and found no 
difference in weight loss at 6 months or 2 years. 48  A meta-analysis of low 
carbohydrate versus low fat diets was in essential agreement stating that low-
carbohydrate diets are at least as effective as low-fat diets at reducing weight and 
improving metabolic risk factors. 49  A systematic review of evidence from 17 diets 
also found that no one diet was superior.29 Similarly, a meta-analysis of “named” 
diets found no significant difference in weight loss between them.42  Thus the best 
current advice is to provide low energy diets that are likely to be followed by the 
patient and provide health benefits.   
A slightly more favourable picture emerges for the Mediterranean style diet. In 
a meta-analysis of nine studies with 1178 patients Mediterranean style diets were 
associated with a significant decline of body weight and BMI and reductions in 
hemoglobin A1c, fasting plasma glucose, and fasting insulin.50   Along with this effect 
on body weight, one version of this dietary pattern can reduce CVD risk.47  
The jury is still out about low glycaemic index/load diets.  A 5 week 
randomized trial found no significant effect on insulin resistance or markers of CVD 
risk.51   A meta-analysis of 14 studies, however, raised concern. Although C-reactive 
protein and fasting insulin did benefit from the low GI/GL diets, there was a 
significant loss of fat free mass leading to caution in recommending the use of low 
glycaemic index diets for weight loss.52 
Very low-calorie diets (VLCD) or very low-energy diets (VLED), defined as 
having 200 and 800 kcal/day provide a lower energy intake that might result in more 
rapid loss of body fat and weight. Some interesting work has shown that such an 
approach can rapidly normalize blood glucose and other risk factors in people with 
type 2 diabetes.  A sSystematic reviews, however, 32,53 suggested that although 
initial weight loss is more rapid, weight change after one year or more is not much 
different from comprehensive or multi-component approaches and does not 
recommend their routine use, although they may be considered if rapid weight loss is 
clinically necessary. In their analysis of commercial programs, Gudzune et al found 
that very-low-calorie (VLCD) programs, which are usually medically monitored 
(Health Management Resources, Medifast, and OPTIFAST) resulted in at least 4.0% 
greater short-term weight loss than counselling, but some attenuation of effect 
occurred beyond 6 months when this duration of data was available.41 
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 Physical Activity (Word Count = 247) 
Increased physical activity is an essential component of comprehensive 
lifestyle intervention for obesity management.  The recommendations in recent US & 
UK guidelines typically prescribe gradually increasing aerobic physical activity (such 
as brisk walking) to reach a goal of >150 minutes/week (equal to >30 minutes/day, 
for at least 5 days each week).29, 32, 54  This has benefits for general health that are 
independent of weight loss.556  Meta-analysis of trials indicated that this results in an 
additional 1 to 1.5kg weight loss over 12 months over and above dietary intervention 
alone.32, 57 There is evidence that a greater amount physical activity (30-45 minutes 
per day) is required to prevent obesity and that for long-term weight maintenance in 
those who have lost weight, 60-90 minutes per day is required, 29, 565  but this is likely 
to require close supervision as part of an intensive programme, which may not be 
practical or sustainable in many clinical settings.58, 59, 60  However, while this is 
effective in the short term in controlled settings, the activities and their benefits are 
not readily sustained, as was found comparing the 1 and 4 year results in the Look 
AHEAD study.36  The type of physical activity (eg aerobic vs resistance; high 
intensity vs low intensity) does not seem to affect overall weight loss, but as more 
intensive activity produces similar weight loss with a reduced time commitment, they 
might be preferable to some; it would therefore seem appropriate to recommend 
programmes that are acceptable to patients.556, 61   
 
Pharmacotherapy (Words = 1232) 
A recent systematic review and clinical guidance sponsored by the Endocrine 
Society 29 promotes the concept that, for patients with obesity, medicating for chronic 
diseases should be with a weight centric focus.  Many medications in use for 
common chronic diseases produce weight gain, and others are associated with 
weight loss, albeit those medications do not have an obesity indication.  Whenever 
possible, patients with obesity should avoid medications associated with gain and 
use weight neutral medications or those associated with loss (Table 1). 31, 62, 63 
Table 1 (Medications that Produce Weight Gain) 
The indications for adding pharmacotherapy to a weight loss effort are history 
of failure to achieve clinically meaningful weight loss (>5%) and to sustain lost 
weight, for patients who meet regulatory prescribing guidelines (BMI >27 kg/m2 with 
one or more co-morbidities or a BMI >30 kg/m2 with or without associated metabolic 
consequences). 29, 31, 32  
Five medications have been approved in the US for chronic weight 
management, and three of these have also been approved in the EU.  [See Table 2.   
for dosing, mechanism of action and efficacy, safety and tolerability of these drugs.  
The data supporting these tables is derived from the prescribing information labelling 
approved by the US FDA].643, 654, 665, 676, 687, 698 Figure 24 shows the sites of action for 
these medications. 
Figure 2 about here 
Table 2.  Medications Approved in EU and/or US: Mechanism of Action, 
Dosing, Efficacy, Tolerability and Safety 
Several guiding principles should be followed when prescribing drugs for 
weight loss.31  First, effective lifestyle support for weight loss should be provided 
during their use. These medications work to reinforce the patient’s attempts to 
change eating behaviours and produce an energy deficit. Second, the prescriber and 
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patient should be familiar with the drug and its potential side effects. Third, unless 
clinically meaningful weight loss occurs after 3 to 4 months, [generally defined as 
more than 4 to 5% in patients without diabetes (In patients with obesity and diabetes 
>3% weight loss can be considered satisfactory)] a new treatment plan should be 
implemented. No one medication is effective in every patient just as not every patient 
is appropriate for every medication.  
Phentermine is a sympathomimetic drug with cardiostimulatory properties. 643 
It has only been studied in short-term trials and is a controlled substance in the US. It 
has abuse potential (albeit small) and small risk of primary pulmonary hypertension, 
thus making its use for managing a chronic disease less than ideal.  Orlistat is a 
pancreatic lipase inhibitor that blocks absorption of 30% of ingested fat when eating 
a 30% fat diet.7069  It is available in most countries world-wide.   Orlistat is among the 
safest drugs in this category 64 and is approved for use in adolescents.710   
Additionally, a study of 4 years duration721 supports its long term safety and efficacy 
and shows that it reduces the development of diabetes mellitus in people with 
prediabetes.  However the drug’s gastrointestinal side effects 654 limit its popularity 
with patients.         
Since 2012, 4 medications have reached the market in the US – lorcaserin, 
732, 743, 754, a combination of phentermine/topiramate ER,765, 776, 787 a combination of 
naltrexone SR/bupropion SR 798, 8079, 80, 81, 82, 823 and liraglutide 3.0 mg.834, 845, 856, 867 
These drugs are required by regulatory agencies in the US and EU to present data 
on >2500 patients and to approximate or exceed 5% greater weight loss than 
placebo (with the EU’s interest in exceeding 10% weight loss) and to demonstrate 
positive effects on a variety of risk factors and disease markers.  All centrally acting 
agents must show evidence of no increase in cardiovascular risk, which is likely to 
require a cardiovascular outcome trial either before or after marketing.have a 
cardiovascular outcome trial, either before or after marketing.  Further, all of these 
drugs were studied with a suicidality rating scale.878  These medications have an 
indication for “chronic weight management” indicating long-term usage, along with 
diet and physical activity in individuals with BMI >30 kg/m2 or a BMI >27 kg/m2 with 
one or more comorbidities.  They are to be used over the long term, not just to 
produce weight loss, but to sustain lost weight.   
Lorcaserin is a specific serotonin 2c receptor agonist.732  Lorcaserin is 
remarkable for its tolerability and low rate of adverse events.  732, 743, 754   
Echocardiograms performed in phase III studies on more than 5200 subjects found 
no statistically significant increase in FDA defined valvulopathy. 665 The drug should 
not be used with monoamine oxidase inhibitors (MAOIs) because of the risk of 
serotonin syndrome. 665 It has not been studied with SSRIs, SNRIs or other 
serotonergic agents and extreme caution should be used in combining it with those 
agents.665    
           The combination of phentermine and topiramate as in extended release (ER) 
formulation (PHEN/TPM ER) uses lower doses of both (7.5/46 mg at the 
recommended dose) than are usually prescribed when either drug is used as single 
agent. 765, 776, 787 This medication is associated with greater mean weight loss than 
other available medications. Topiramate is associated with fetal toxicity (oral clefts) 
889  and a pregnancy test prior to initiating therapy and monthly thereafter is 
recommended.676  The most common side effects include paresthesias, dizziness, 
dysgeusia, insomnia, constipation and dry mouth.676 A rare side effect of topiramate 
is acute myopia with glaucoma and the drug is contraindicated in glaucoma.676  The 
combination of PHEN/TPM ER is also contraindicated in hyperthyroidism and within 
14 days of treatment with monoamine oxidase inhibitors (MAOIs).676 Other rare 
potential adverse risks include kidney stones (associated with topiramate) and 
increased heart rate (associated with phentermine) in patients susceptible to 
sympathomimetic drugs.676    
The combination of naltrexone SR/bupropion SR was approved in the US in 
2012 and in the EU in 2015.798, 8079, 80, 81, 823  Bupropion is a mild reuptake inhibitor of 
dopamine and norepinephrine. Naltrexone, an opioid antagonist has minimal effect 
on weight loss on its own.   Naltrexone is thought to block inhibitory influences of 
opioid receptors activated by the β-endorphin released in the hypothalamus that 
stimulates feeding, thus allowing the inhibitory effects of α-melanocyte stimulating 
hormone (α-MSH) to reduce food intake.82 Naltrexone SR/ bupropion SR can 
increase blood pressure; the combination should only be prescribed to patients with 
controlled hypertension and the patient’s blood pressure should be monitored in the 
early weeks of therapy.687  Despite these signals, absence of increased events in the 
interim analysis of a A cardiovascular outcome trial conducted before marketing 
allowed approval.687 Another cardiovascular outcome trial was required post-
marketing.  Tolerability issues, chiefly nausea on initiating the drug mandate a dose 
escalation over four weeks.  All antidepressants in the US are required to carry a 
black box warning of suicidality and the combination’s label includes this.687  
However, there was no signal for suicidality in phase III studies. 78, 79, 80, 81, 83   
Liraglutide is a GLP-1 agonist with a 97% homology to GLP-1 which extends 
its circulating half-life. It has been used for management of diabetes at doses up to 
1.8 mg, given by injection.  It is now approved in the US and EU for chronic weight 
management at a dose of 3.0 mg. 834, 845, 856, 867  Nausea has been one of the 
principal complaints in patients injecting this drug and a slow dose escalation over 5 
weeks is prescribed.698   There is also a small, but significant increase in heart rate, 
but blood pressure tends to fall.698 GLP-1 agonists are associated with thyroid C cell 
tumors in animals, but this has not been demonstrated with certainty in humans.698  
Liraglutide should not be prescribed in patients with family or personal history of 
medullary thyroid cancer or multiple endocrine neoplasia.698  Acute pancreatitis, gall 
bladder disease and hypoglycemia in diabetics are safety issues that require 
managing if they occur.   
 
Surgical Procedures in the Treatment of Obesity (Word Count = 508) 
Bariatric surgery has rapidly become adopted as a treatment option for severe 
obesity, particularly since the advent of lower risk laparoscopic procedures, with 
nearly half a million procedures performed worldwide in 2013.8990  A range of 
procedures are now well-established which result in varying degrees of weight loss;  
each procedure has its own risks and benefits which need to be considered carefully 
with each patient  (Table 3).901 
Table 3 about here 
Longer term studies of outcomes following bariatric surgery have generally 
shown favourable results.  The Swedish Obese Subjects study followed 2000 
patients for up to 20 years after surgery including banded gastroplasty, gastric 
banding and Roux-en-Y gastric bypass performed by open techniques which have 
since been replaced by laparoscopy.  There was a 24% reduction in mortality, mainly 
due to reduced risk of myocardial infarction and cancer (in women), compared to an 
observational control group.912, 923  Many other co-morbidities, such as type 2 
diabetes and sleep apnoea are also improved, and patients report consistent 
improvements in quality of life.934 
 Particularly striking and rapid improvements in glucose control have been 
seen in patients with type 2 diabetes, especially following gastric bypass, suggesting 
that part of the metabolic improvement is independent of weight loss.945  Head to 
head randomised controlled trials against medical treatment for type 2 diabetes 
consistently show greater improvements in glucose control and other risk factors in 
the surgical group.956, 967, 978, 99  Observational data also suggest that future risk of 
diabetes-related micro- and macrovascular complications are also reduced.999  This 
has led to the concept of ‘metabolic’ surgery, and recent revision of guidelines and 
recommendations to lower thresholds for considering surgery in people with type 2 
diabetes, particularly of recent onset, to include patients with a BMI between 30 and 
35 kg/m2, 32, 100100, 1011 and a move away from BMI as the main criterion used to 
assess eligibility for surgery.100100 These encouraging data need to be put into the 
context of potential risks and side-effects of surgery, which for some patients can be 
distressing or disabling.  Although mortality is low for modern laparoscopic surgery, 
re-operation rates for surgical complications are significant, particularly for gastric 
banding (Table 3).  Some patients find it hard to adapt to the profound changes in 
the amount and type of food they can eat once they have had the procedure and 
lifelong replacement therapy and monitoring is required for nutritional vitamin and 
mineral deficiencies, particularly after malabsorptive surgery.  Dumping syndrome  
gastro-oesophageal reflux and hypoglycaemia can be very distressing and a 
challenge to treat.1033  Weight regain can also be a significant problem, and 
revisional surgery carries greater risks and no guarantee of success; 1044 there is an 
increasing focus on lifestyle programmes after bariatric surgery to reduce the risk of 
this occurring. 32 
 From a clinical perspective it is essential that patients and clinicians 
considering referral for bariatric surgery are fully aware of the risks and benefits; 
good practice might include provision of a detailed education session, attendance at 
patient support groups as well as detailed lifestyle advice and psychological support 
both before and after surgery. 1055 
 
Controversies: (words = 529) 
As with other areas of medicine, not all issues have been resolved to 
everyone’s satisfaction.  Below is a list of some of the controversies that are up for 
continuing debate and resolution.   
Should obesity be a strong focus of undergraduate medical education or 
should it be taught primarily at the most graduate level? 1066  Weight bias is 
commonly observed among medical students as well as experienced doctors to 
stigmatize patients.1077  This stigma might be reduce if the complexities of obesity 
were introduced earlier.  This stigma might also partly explain why obesity is an 
under-diagnosed and under-treated condition despite its high prevalence. 1088 
Who needs to lose weight and what is the best way to decide?  Is BMI an 
appropriate measure to decide who should lose weight ?1099  If not appropriate in 
itself what will improve clinical decision making?  Is the percentage of weight 
reduction  acceptable as a primary endpoint given that several additional benefits not 
requiring weight loss can be of equal clinical relevance? Should a weight- or BMI-
centric approach should be abandoned in favor of a wider array of endpoints such as 
improvements in cardiometabolic variables. Introduction of additional criteria for 
identifying patients at high risk, should be discussed.  
A third controversy revolves around whether there are people who are obese 
and “metabolically healthy” the so-called Metabolic Healthy Obesity or MHO.   
Individuals with metabolically healthy obesity (MHO) may not improve their cardio-
metabolic risk factors significantly after weight loss interventions and may therefore 
not benefit to the same extent as obese patients with metabolic comorbidities. There 
is controversy as to whether individuals labeled as “metabolic-health-obese” are 
really healthy, especially since no general agreement exists on accepted criteria to 
define those with MHO.11010, 1111 Moreover, there is still controversy as to whether 
MHO can be considered an established phenotype or rather represents a transient 
stage toward ill-health  with ageing, behavioural and environmental factors. MHO 
appears to be a relatively transient condition with a considerable percentage of these 
individuals exhibiting similar metabolic derangements to those observed in obese 
metabolically altered patients as time passes.1122, 1133 Conversely, non-obese 
individuals according to BMI but obese based on body fat distribution exhibit 
elevated  cardiometabolic risk factors 1144, 1155, and should be identified and treated 
irrespective of BMI. 
 
One of the major uncertainties for patients with obesity is whether current 
pharmacological treatments increase, reduce or are neutral with respect to 
cardiovascular events. This is currently under investigation in the Cardiovascular 
Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects 
With Cardiovascular Risk Factors (The Light Study) (NCT01601704) and Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A 
Long Term Evaluation (LEADER®) (NCT01601704).     
The question of whether obesity should be treated in primary care or by 
specialists with training in obesity is one that will have major impacts on health 
services. A number of studies (NCT00991640, NCT01967797 and NCT01606813) 
are due to report on this problem in the next few years. 
Obesity raises a number of societal controversies. Government taxes on 
“unhealthy” foods has been tried in some countries (Denmark for example) but with 
variable results. Should governments subsidize commercial weight loss programs 
that have proven to be successful?  1156 
 
Legends: 
Appendix fFigure 1.  The Global Pandemic of Obesity Illustrated by the Prevalence of 
Obesity by Country for Males over 20 Years of Age. (Ref 5).   
 
Appendix fFigure 2. Relation of body mass index to mortality in pooled data sets with 
over  900,000 people and the effect of specific causes of death Ref 21). All-cause 
mortality versus BMI for each sex in the range 15-50 kg/m2 (excluding the first 5 
years of follow-up)  Relative risks at age 35-89 adjusted for age at risk, smoking and 
study, were multiplied by a common factor (i.e., floated) to make the weighted 
average match the PSC mortality rate at age 35-79 years.  Area of the square is 
inversely proportional to the variance of the long risk.    
 
Figure 13. Factors that predict weight loss in the Look AHEAD study (Refs 36, 40)  
The results in panels A, B and C indicate the greater weight loss at 1-year 
associated with greater proportion of visits, attended, minutes per week of physical 
activity, and greater meal replacement use.  Black bars indicate the first quartile and 
light gray ones the 4th quartile.  Panel D shows the weight loss at years 4 and 8 by 
percent weight loss at one month (left side) and 2 months (right side).  The tertiles of 
weight ranges are shown below each set of bars. 
Figure 4.  
 
Figure 24. Targets for anti-obesity drugs.  White boxes indicate specific drugs 
located next to the target upon which they are acting. Inside the white 
boxes green names stand for already approved drugs, whereas red 
names represent drugs in phase I-III development. The right hand 
panel summarizes the neurotransmitters and pathways involved in the 
central nervous system in energy homeostasis, while the left hand 
panel represents the mechanisms operative in the periphery. The 
intermediate area represents where the effects of both central and 
peripheral actions converge, namely on the two main components of 
the energy balance equation, i.e. energy intake and expenditure. Note 
that most of the currently approved drugs are working centrally where 
stimulation of the POMC/CART pathway has anorexigenic effects, 
while the NPY/AGRP pathway exerts orexigenic effects. The 
interaction with the multiple receptors present in neurones of the 
hypothalamus determines the balance between orexigenic and 
anorexigenic influences. Most of the drugs currently tested in clinical 
trials are aimed at peripheral systems. Thus, thyroid analogues and 3 
adrenergic agonists induce thermogenesis via activation of brown 
adipose tissue (BAT), thereby increasing energy expenditure. Enzymes 
involved in lipid metabolism such as DGAT, FAS, MetAP2 and NQO1 
are also being targeted. The gut microbiome as well as the regulation 
of bile acids represent further targets to combat obesity. The lipase and 
SGLT2 inhibitors favour energy loss via the gastrointestinal and renal 
elimination of fat and glucose, respectively. Agonism of pancreatic and 
intestinal hormones like amylin and GLP-1 has also been shown to be 
useful for weight loss. 
Abbreviations:  DGAT1 = diacylglycerol O-acyltransferase aminotransferase 1; FAS 
= fatty acid synthase; MetAP2 = methionyl aminopeptidase 2; PexRAP inh = 
peroxisomal reductase activating PPAR inhibitor; NQO1 = NAD(P)H 
dehydrogenase:quinone oxidoreductase 1; SGLT2 = sodium-glucose-linked 
transporter 2; inh = inhibitor; BAT = brown adipose tissue; WAT = white adipose 
tissue; GABA = -aminobutyric acid; DA = dopamine; NE = norepinephrine; CB = 
cannabinoid; H = histamine; 5HT = serotonin; ObR = leptin receptor; GHSR = growth 
hormone secretagogue receptor; AGRP = Agouti-related peptide; CART = cocaine 
amphetamine-related transcript; NPY = neuropeptide Y; Y1R = Y1 receptor; Y2R = 
Y2 receptor; Y5R = Y5 receptor; POMC = proopiomelanocortin C; GLP1R = 
glucagon-like peptide 1 receptor; -MSH = -melanocyte-stimulating hormone; 
MCH1R = melanin-concentrating hormone 1 receptor; MC3R = melanocortin 
receptor type 3; MC4R = melanocortin receptor type 4; -OR = -opioid receptor;  
5HT2c = serotonin receptor type 2c. 
 
 
 
 
Tables: 
Table 1: Medications Affecting Weight Gain and Alternative Approaches 
Table 2: Medications for weight management: Mechanism of action, availability 
and dosing.  (Ref: US Product Label, except where noted) 
Table 3: Effect of the Principal Surgical Procedures for Treatment of Obesity 
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October 12, 2015 
 
Dr. Stuart Spencer 
The Lancet  
125 London Wall  
London, EC2Y 5AS, UK 
 
Dear Stuart 
 
Manuscript: THELANCET-D-15-01286R4, Management of Obesity 
 
Good morning.  The four of us want to thank you for “sticking” with us while we 
complete the reworking of this paper.    In this version we have:  
Moved 2 figures (formerly Figure 1 and Figure 2) to the appendix.   
Revised Table 1 to include the suggestions of the reviewer.   
Included a search strategy.   
Added a few references, removed a few others and aligned the numbering. 
 
We hope that all of these changes will make the paper acceptable. 
I have one questions about copyright for the figures. Both Appendix Figure 1 and 2 were 
originally published in Lancet, so I presume you hold the copyright.  Figure 3 is a 
composite of 3 panels (left hand pair and top right) that have been redrawn and the 
lower right panel which was drawn from data in a different paper.   If we send this figure 
to a journal it will be unrecognizable as one they have copyrighted.  How should I 
proceed? 
 
Below is the point-by-point response to the Editorial and Referee comments: 
 
COMMENTS TO THE AUTHOR: 
 
Editors 
 
There are some specific points that editors raised in addition to those that are our 
standard requirements. 
 
1. From our psychiatry editor: Why mention only antidepressants being associated with 
weight gain, and not antipsychotics?  And why only pharmacological alternatives and 
not psychotherapy? 
 
RESPONSE:  We added “antipsychotics” to the examples of medication associated with 
gain in the fast facts section. Since we were targeting primary care provides, we limited 
Table 1 to medications they were most likely to prescribe and manage.  However, this 
has been revised based on the comments above.  We have inserted relevant 
medications for antipsychotics and anti-convulsants and expanded the antidepressants 
to include mood stabilizers.  We have followed Endocrine Society guidelines based on a 
*Reply to Reviewers Comments
systematic evidence review, and although psychotherapy was not mentioned in this 
document, we included it in the table as weight neutral. 
 
2. Please include a conflicts of interest statement in the main text (this does not count 
towards your word count) 
 
RESPONSE:   Here is the conflict of interest statement: 
The authors identify the following potential conflicts of interest:  Dr. Bray is a consultant 
to Herbalife International and Medifast; a member of the Speakers Bureau for Novo 
Nordisk Pharmaceuticals and Takeda Pharmaceuticals; receives royalties from Up-to-
Date and Handbook of Obesity; Dr. Frühbeck is a consultant to Novo Nordisk; Dr. Ryan 
is a consultant to Novo Nordisk Pharmaceuticals, Takeda Pharmaceuticals, Eisai 
Pharmaceuticals, Vivus Pharmaceuticals, Janssen Pharmaceuticals, Amgen 
Pharmaceuticals, Real Appeal, Gila Therapeutics, Tulip Medical and Scientific Intake 
and is on the speakers bureau for Novo Nordisk Pharmaceuticals, Takeda 
Pharmaceuticals, Eisai Pharmaceuticals and Vivus Pharmaceuticals, and has equity 
ownership in Scientific Intake; Dr. Wilding received grant funding from Novo Nordisk 
and AstraZeneca, and is a consultant to Novo Nordisk, Janssen Pharmaceuticals, 
AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, and  Pfizer 
Pharmaceuticals.  
 
3.  We need a search strategy, please 
 
RESPONSE:  A search strategy was inserted just after FAST FACTS 
 
4.  At least 2 of the non-text items (tables or figures) need to go to the web appendix 
 
RESPONSE:  The group voted to move figures 1 and 2 to the appendix and leave only 
one figure and 3 tables which have been appropriately edited. 
 
5.   Please provide permission to use the recycled figures (except The Lancet figure) 
 
RESPONSE:  Appendix figure 1 is from Lancet;  Appendix figure 2 is from Lancet PLUS 
the right hand box which uses data from the same paper; Figure 3 is a composite.  The 
left 2 panels and the top right panel have been published several places and were 
redrawn from Obesity Supplement.  The lower right hand panel is drawn from data in 
Ref 40.  I am not sure how to get permission for a figure which doesn’t exist per se.   
Please advise.  Figure 4 is original 
 
Reviewer #5: This SEMINAR paper is well crafted, reads well, and provides adequate 
and meaningful information to the practicing clinician. 
 
A few suggestions that are not critically important: 
 
Page 8 (of the merged PDF file): Suggest deleting the following text: 
"In a meta-analysis of commercial programs in the US, found that at 12 months Weight 
Watchers participants achieved at least 2.6% more weight loss than the 
control/education group; the Jenny Craig program weight loss was at least 4.9% greater 
at 12 months than in the control/education and counselling group; the Atkins program 
resulted in 0.1% to 2.9% greater weight loss at 12 months than counselling; and the 
Nutrisystem weight loss program was at least 3.8% greater at 3 months than the 
control/education and counseling control groups." 
 
RESPONSE:  I made this deletion and inserted this wording” 
“There are several commercial weight loss programmes, and some individuals may 
benefit from them. The costs and methods of delivering treatment vary which may affect 
compliance and real-world applicability.  These programmes provide on the average 
about 3% weight loss over a year, but long-term compliance is generally poor.   Studies 
of longer than a year are sparse.” 
 
Suggest replacing the above with a broad-stroke statement that several commercial 
weight loss programmes exist. Some individuals might benefit from these approaches, 
costs and treatment delivery methods vary thus affecting compliance and real-world 
applicability, and they provide on the average about 3% weight loss over a year, studies 
longer than a year are sparse, and long-term compliance is generally poor. 
 
Reason for the suggestion: This was a much-criticised meta-analysis. Included studies 
had methodological limitations and varying sample sizes and high dropout rates. A 
concern is that some commercial programmes could use inclusion of numbers in this 
prestigious paper as an advertisement whereas a meta-analysis showed no differences 
among the 'named' diets.  
 
 
Page 13: "These drugs are required by regulatory agencies in the US and EU to present 
data on >2500 patients and to approximate or exceed 5% greater weight loss than 
placebo (with the EU's interest in exceeding 10% weight loss) and to demonstrate 
positive effects on a variety of risk factors and disease markers." 
 
EMA's June 2014 draft guidance does not insist on 10% total weight loss. Rather, it 
states: Demonstration of a clinically significant degree of weight loss of at least 5- 10% 
of baseline weight, which is also at least 5% greater than that associated with placebo, 
is considered to be a valid primary efficacy criterion in clinical trials evaluating new anti-
obesity drugs.  Please revise your statement accordingly. 
 
RESPONSE:  Thank you for this comment.  We thought that since the EU labels focus 
on providing results for 10% weight loss, this comment might be appropriate.  However, 
it is better to simply omit it which we have done. 
 
 
Page 13: "All centrally acting agents must have a cardiovascular outcome trial, either 
before or after marketing." 
The above statement is not accurate.  
 
In March 2012 the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) 
discussed and voted on CV risk assessment for weight loss drugs similar to 
requirements for diabetes drugs. EMDAC voted 17 to 6 to require pre-approval 
assessments to exclude some degree of CV risk for all weight loss drugs, even in the 
absence of a CV signal or theoretical risk. This requirement is not just for "centrally 
acting agents"; rather, it is a requirement for all weight loss drugs. However, FDA is yet 
to establish a clear guidance for CV risk assessment for weight management drugs.  
 
RESPONSE:  In order to address this comment and the fact that there was no CVOT for 
orlistat, we revised the statement to say that “All agents must show evidence of no 
increase in cardiovascular risk, which is likely to require a cardiovascular outcome trial, 
either before or after marketing. 
 
Page 15: "Despite these signals, absence of increased events in a cardiovascular 
outcome trial conducted before marketing allowed approval. 
 
Please note that this was based on an interim analysis. A full-size trial to rule out 
increased risk of MACE has not been completed yet.  
 
 
RESPONSE:  We edited this section as follows:  “Despite these signals, absence of 
increased events in the interim analysis of a cardiovascular outcome trial conducted 
before marketing allowed approval.67 Another cardiovascular outcome trial was required 
post-marketing.”   
 
References 75 and 77 are identical. I believe 77 should be: Allison DB et al, published 
in the journal Obesity, 2012. 
 
RESPONSE:  Thank you for picking up this duplication.  Reference 77 in the older 
version should have been Allison et al and this correction has been made and the new 
reference inserted.  All references have been appropriately renumbered and the text 
checked against them. 
 
To keep it consistent, delete references of proof-of-concept and phase II trials of 
naltrexone/bupropion and keep only the phase III trials. 
 
RESPONSE:  Proof of concept trials were deleted. 
 
Table 1: There are no consistent data with regard to the effects of antidepressants on 
body weight. A recently very large study of electronic medical records published in 
JAMA Psychiatry (Aug 2015) revealed less weight gain with two tricyclics - amitriptyline 
and nortriptyline, a finding that conflicts with generally held beliefs.  
 
RESPONSE:  We relied on the systematic evidence review conducted by the Endocrine 
Society for their Guidelines which were published in January 2015.  There are no 
serious contradictions across review, so we added this citation:  Blumentahl SR, Castro 
VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, Weilburg JB, Erb JL, Churchill 
SE, Kohane IS, Smoller JW, Perlis RH.  An electronic health records study of long-term 
weight gain following antidepressant use.  JAMA Psychiatry 2014 Aug;718)”889-896. 
 
Lacking data from direct comparison trials, here is suggested placement for various 
antidepressants: 
 
Weight gain: 
Monoamine oxidase inhibitors, some tricyclics (e.g., doxepin), some SSRIs (most 
prominent being paroxetine), mirtazapine 
 
Weight neutral: 
Some SSRIs (e.g., citalopram, fluvoxamine, vortioxetine), duloxetine, venlafaxine 
 
Weight gain: (We think you mean weight loss) Bupropion, fluoxetine (short-term) 
 
RESPONSE:  We resolved this issue of competing reviews by merging both and citing 
the JAMA Psychiatry review in addition to the ENDO Guidelines.  Please note: the table 
has been expanded to address the Lancet Psychiatry Consultant. 
 
Table 2: Weight loss shown for phentermine (12% vs. 4.5% with placebo) is probably 
exaggerated and not in line with the results from the Haddock et al meta-analysis. This 
weight loss was based on the 1968 Munro et al study which enrolled 108 women who 
were placed on a 1000 kcal/d diet and assigned to 30 mg/d phentermine continuously, 
30 mg/d of phentermine intermittently (on for a month and off for a month), or placebo 
for 9 months. The paper reported weight loss data for 64 completers only (17 
continuous phentermine, 22 intermittent phentermine, and 25 placebo). Thus the 
reported weight loss of 12.2 kg for continuous phentermine was the average weight loss 
for 17 completers only. Hence, if you are showing these data, please describe the 
limitations of the Munro et al study.  
 
RESPONSE:  We agree with these comments.   We had adapted this table from the 
Endocrine Society Guidelines and that is where the phentermine data was provided.  
For this purpose, since we are relying on data from product labels, we think it best to 
indicate that 1) phentermine is only indicated for short term use in the US, 2) there is 
NO efficacy data supplied in the Adipex label and that 3) we can’t say anything about 
phentermine efficacy.  See revision in the table. 
Sincerely yours, 
 
George A. Bray, MD 
For the authors 
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*Area of square is inversely proportional to the variance of the log risk.  
Data based on 57 prospective studies encompassing ~900,000 adults, 35–89 years of 
age. BMI = body mass index. 
Prospective Studies Collaboration. Lancet. 2009;373:1083-1096. 
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Overall mortality  30% 
 
Diabetes mellitus  116% 
Hepatic disease 80% 
Renal disease 60% 
Vascular disease 40% 
Malignancy 10% 
 
Table 1:  Medications Affecting Weight Gain and Alternative Approaches 
 
Drug Class Weight Gain Weight Neutral Weight Loss 
Anti-Diabetics Insulin 
Sulfonylureas (many) 
Meglitinides (Nateglinide; 
Repaglinide) 
Glitazones  (Pioglitazone 
& Rosiglitazone) 
Dipeptidyl peptidase-4 
inhibitors (many) 
Metformin 
Pramlintide 
GLP-1 agonists (Exenatide; 
liraglutide; others) 
Sodium-glucose co-transporter-2 
inhibitors (Canagliflozin and others) 
Anti-depressants/ 
Mood stabilizers 
Monoamine Oxidase 
Inhibitors (Many) 
Tricyclics (some, ie 
doxepin) 
Serotonin Reuptake 
Inhibitors (SSRI) (Some, 
i.e. paroxetine ) 
mirtazapine 
Lithium  
Citalopram, Fuvoxamine, 
Vortionzetine, Duloxetine, 
Venlafaxine, Nefazodone 
Sertraline (<1 year) 
psychotherapy 
Venlafaxine 
Bupropion 
Fluoxetine (short term) 
Anti-psychotics Clozapine 
Risperidone 
Olanzapine 
Quetiapine 
Haloperidol 
Perphenazine 
Quetiapine 
Ziprasidone 
Aripiprizole 
psychotherapy 
 
Anticonvulsants Carbamazepine 
Gabapentin 
Valproate 
Lamotrigine? Topiramate 
Zonisamide 
Anti-histamines Cycloheptadine 
Diphenhydramine 
Doxepin 
Steroid inhalers 
Decongestants 
 
Adrenergic 
blockers 
Propranolol 
Doxazosin 
Angiotensin converting 
enzyme inhibitors (ACEI) 
 
Table
Angiotensin receptor 
blockers (ARBs) 
Calcium channel blockers 
Adrenal steroids Corticosteroids Non-steroidal anti-
inflammatory drugs 
 
Oral 
contraceptives 
   
tid = three times a day; bid = twice a day; ER = extended release; SR = sustained release; MAOI = monoamine oxidase inhibitor; SNRI = 
Serotonin-norepinephrine Reuptake Inhibitor; SSRI = Selective Serotonin Reuptake Inhibitor; a = Phentermine only approved in the US for “a few 
weeks” usually consider < 12 weeks; b = randomized controlled trials lasting more than 52 weeks; c = Data from Munro (Munro JF Br Med J. 1968 
Feb 10;1(5588):352-4) after 9 months of treatment;  d = Assuming average patient in the Orlistat and placebo groups weighed 100 kg at baseline.  
(Phentermine has many trade names in the US; Orlistat = Xenical worldwide; Lorcaserin = Belviq in US; Phentermine/topiramte = Qsymia in the 
US; Naltrexone SR/Bupropion = Contrave in the US and Mysimba in Europe; Liraglutide for obesity = Saxenda worldwide; liraglutide for diabetes 
Victoza )  
 
 
 
 
 
 
 
 
 
  
Table 2.  Medications for weight management: Mechanism of action, availability and dosing.  
 Information is from US Product Label, except where noted. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/  
Medication 
and 
recommend
ed dose 
Mechanism of 
action  
Available 
for Chronic 
Use unless 
otherwise 
stated 
Mean percent weight 
loss  with drug/ with 
placebo  
 
Advantages Disadvantages 
US 
 
EU       
 
 
Placebo 
 
Drug 
Phentermine 
15 mg – 30 
mg 
Oral 
Sympathomimetic  
For 
short 
term 
use 
No  
Not 
stated in 
label 
 
Not stated 
in label 
Inexpensive 
 
Side effect profile 
No long-term data b 
Orlistat  
120 mg tid, 
before meals 
Oral 
Pancreatic lipase 
inhibitor 
Yes Yes -2.6%d  
 
-6.1%d 
 
Not absorbed  
Long-term data b 
Modest weight loss 
Side-effect profile 
Lorcaserin 
10 mg bid 
Oral 
5-HT2C serotonin 
agonist with little 
affinity for other 
serotonergic 
receptors 
Yes No -2.5%  -5.8% Mild Side effects 
Long-term data b 
Expensive 
Modest weight loss 
Phentermine/ 
Topiramate 
ER 
7.5 mg/46 
mg; 15mg/92 
mg indicated 
as rescue 
Oral 
(requires 
titration) 
Sympathomimetic 
Anticonvulsant 
(GABA receptor 
modulation, 
carbonic 
anhydrase 
inhibition, 
glutamate 
antagonism) 
Yes No -1.2%  -7.8% 
(Mid 
Dose) 
-9.8%(Full 
Dose) 
Robust weight loss 
Long-term data b 
Expensive 
Teratogen 
Naltrexone Opioid receptor Yes Yes -1.3%  -5.4%  Greater weight loss Moderately expensive 
SR/ 
Bupropion 
SR 
32 mg/ 360 
mg 
Oral  
(requires 
titration) 
antagonist 
Dopamine & 
noradrenaline 
reuptake inhibitor 
Reduces food addiction 
Long-term data b 
Side-effect profile 
Liraglutide  
3.0 mg 
Injection 
(requires 
titration) 
 
GLP-1 receptor 
agonist  
Yes Yes -3%  -7.4% 
(Full dose) 
Side effect profile 
Long-term data b 
Expensive 
Injectable 
 
  
 Table 3:  Surgical Procedures for Treatment of Obesity 
 
 
Procedure Weight loss 
after 3 years 
Δ BMI (kg 
/m2) (95% CI)  
 
Effects on 
type 2 
diabetes 
remission 
(%) (95% CI)  
at  years –  
Mortality 
% (95% CI) 
<30 day 
>30day 
 
Re-
operation 
rate  
%(95% 
CI) 
 
Complications 
% (95% CI) 
Adjustable 
gastric 
banding (AGB) 
−11.43 
(−18.14 to 
−4.72) 
67.58 (49.51-
82.83) 
0.07 (0.02-
0.12) 
0.21 (0.08-
0.37) 
7.01 
(3.99-
11.24) 
7.80 (3.90-
13.00) 
 
Sleeve 
Gastrectomy 
(SG) 
−16.78 
(−20.57 to 
−12.99) 
85.53 (72.69-
94.07) 
0.29 (0.11-
0.63) 
0.34 (0.14-
0.60) 
2.96 
(1.70-
4.71) 
8.90 (5.60-
13.00) 
 
Roux-en-Y 
gastric bypass 
(RGB) 
−21.88 
(−27.96 to 
−15.79) 
92.83 (85.29-
97.21) 
0.38 (0.22-
0.59) 
0.39 (0.01-
0.86) 
5.34 
(4.48-
6.48) 
12.00 (7.30-
17.00) 
 
 
Data in table are from Chang (2014).  Note that for this analysis, surgical procedures were grouped: AGB includes 
laparoscopic gastric banding and Swedish band; SG includes sleeve gastrectomy and vertical banded gastroplasty; RGB 
includes laparoscopic and open procedures as well as biliopancreatic diversion with or without duodenal switch. 
 
 
  
Supplemental Table  Common side effects and contraindications and 
warnings for medications used to treat patients who are overweight 
or obese.  
Information is from US Product Label, except where noted.89-95  
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ 
Medication  Common Side Effects Contraindications and Warnings 
Phentermine 
15 -30 mg  
 
 Headache 
 Elevated Blood Pressure and 
Pulse 
  
 Insomnia 
 Dry mouth 
 Constipation 
 Anxiety 
 Contraindicated with history of 
cardiovascular disease 
 Use with caution in patients with 
even mild hypertension 
 Contraindicated with MAOIs, 
hyperthyroidism, glaucoma, history 
of drug abuse 
 Primary pulmonary hypertension 
(rare) 
 Hypoglycemia with diabetes 
 Only indicated for short-term use –
“a few weeks” 
Orlistat  
120 mg tid,  
 
 Steatorrhea 
 Oily spotting 
 Flatulence with discharge 
 Fecal urgency 
 Oily evacuation 
 Increased defecation 
 Fecal incontinence 
 Contraindicated in pregnancy 
 Warning: ↑cyclosporine exposure 
 Liver failure (rare) 
 Requires co-administration of 
multiple vitamin 
 Increased risk of gall bladder 
disease  
Lorcaserin 
10 mg bid 
 
 Headache 
 Dizziness 
 Nausea 
 Dry mouth 
 Fatigue 
 Constipation 
 Contraindicated in pregnancy 
 Use with caution with SSRI, SNRI, 
MAOIs, St John’s wort, Triptans, 
Bupropion, Dextromethorphan 
 Contraindicated in pregnancy 
Phentermine/ 
Topiramate ER 
7.5 mg/46 mg 
 Insomnia 
 Dry mouth 
 Constipation  
 Paresthesias 
 Dizziness 
 Dysgeusia 
 Contraindicated in pregnancy  
 Fetal toxicity; monthly pregnancy 
test suggested 
 Contraindicated with 
hyperthyroidism, glaucoma 
 Do not use with MAOIs or 
sympathometic amines 
 Acute myopia (rare) 
Naltrexone SR/ 
Bupropion SR 
32 mg/ 360 mg 
 
 Nausea 
 Constipation  
 Headache 
 Vomiting 
 Dizziness 
 Boxed warning: suicide risk in 
depression 
 Contraindicated in pregnancy 
 Contraindicated in seizure 
disorders, uncontrolled 
hypertension, glaucoma 
 Do not use with opiods, MAOIs 
 Hepatotoxicity (rare) 
Liraglutide  
3.0 mg 
 
 Nausea 
 Vomiting 
 Diarrhea 
 Constipation 
 Headache 
 Dyspepsia 
 Fatigue 
 Dizziness 
 Abdominal pain 
 Boxed warning: thyroid C cell 
tumors in rodents 
 Contraindicated with personal or 
family history of medullary thyroid 
cancer or multiple endocrine 
neoplasia. 
 Pancreatitis 
 Hypoglycemia in diabetes 
 Increased risk of gall bladder 
disease 
tid = three times a day; bid = twice a day; ER = extended release; SR = sustained release; MAOI = monoamine oxidase inhibitor; SNRI = 
Serotonin-norepinephrine Reuptake Inhibitor; SSRI = Selective Serotonin Reuptake Inhibito 
 
Table 1:  Medications Affecting Weight Gain and Alternative Approaches 
 
Drug Class Weight Gain Weight Neutral Weight Loss 
Anti-Diabetics Insulin 
Sulfonylureas (many) 
Meglitinides (Nateglinide; 
Repaglinide) 
Glitazones  (Pioglitazone 
& Rosiglitazone) 
Dipeptidyl peptidase-4 
inhibitors (many) 
Metformin 
Pramlintide 
GLP-1 agonists (Exenatide; 
liraglutide; others) 
Sodium-glucose co-transporter-2 
inhibitors (Canagliflozin and others) 
Anti-depressants/ 
Mood stabilizers 
Monoamine Oxidase 
Inhibitors (Many) 
Tricyclics (some, ie 
doxepin) 
Serotonin Reuptake 
Inhibitors (SSRI) (Some, 
i.e. paroxetine ) 
mirtazapine 
Lithium Tricyclics  
Monoamineoxidase 
inhibitors (Many) 
Serotonin reuptake 
Inhibitors (SSRI) (Many) 
 
Citalopram, Fuvoxamine, 
Vortionzetine, Duloxetine, 
Venlafaxine, Nefazodone 
Sertraline (<1 year) 
psychotherapy 
Venlafaxine 
Bupropion 
Fluoxetine (short term) 
Anti-psychotics Clozapine 
Risperidone 
Olanzapine 
Quetiapine 
Haloperidol 
Perphenazine 
Quetiapine 
Ziprasidone 
Aripiprizole 
psychotherapy 
 
Anticonvulsants Carbamazepine 
Gabapentin 
Valproate 
Lamotrigine? Topiramate 
Zonisamide 
Table
Anti-histamines Cycloheptadine 
Diphenhydramine 
Doxepin 
Steroid inhalers 
Decongestants 
 
Adrenergic 
blockers 
Propranolol 
Doxazosin 
Angiotensin converting 
enzyme inhibitors (ACEI) 
Angiotensin receptor 
blockers (ARBs) 
Calcium channel blockers 
 
Adrenal steroids Corticosteroids Non-steroidal anti-
inflammatory drugs 
 
Oral 
contraceptives 
   
tid = three times a day; bid = twice a day; ER = extended release; SR = sustained release; MAOI = monoamine oxidase inhibitor; SNRI = 
Serotonin-norepinephrine Reuptake Inhibitor; SSRI = Selective Serotonin Reuptake Inhibitor; a = Phentermine only approved in the US for “a few 
weeks” usually consider < 12 weeks; b = randomized controlled trials lasting more than 52 weeks; c = Data from Munro (Munro JF Br Med J. 1968 
Feb 10;1(5588):352-4) after 9 months of treatment;  d = Assuming average patient in the Orlistat and placebo groups weighed 100 kg at baseline.  
(Phentermine has many trade names in the US; Orlistat = Xenical worldwide; Lorcaserin = Belviq in US; Phentermine/topiramte = Qsymia in the 
US; Naltrexone SR/Bupropion = Contrave in the US and Mysimba in Europe; Liraglutide for obesity = Saxenda worldwide; liraglutide for diabetes 
Victoza )  
 
 
 
 
 
 
 
 
 
  
Table 2.  Medications for weight management: Mechanism of action, availability and dosing.  
 Information is from US Product Label, except where noted. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/  
Medication 
and 
recommend
ed dose 
Mechanism of 
action  
Available 
for Chronic 
Use unless 
otherwise 
stated 
Mean percent weight 
loss  with drug/ with 
placebo  
 
Advantages Disadvantages 
US 
 
EU       
 
 
Placebo 
 
Drug 
Phentermine 
15 mg – 30 
mg 
Oral 
Sympathomimetic Yesa 
For 
short 
term 
use  
No -4.5%c 
Not 
stated in 
label  
-12%c 
Not stated 
in label 
Inexpensive 
Greater weight loss  
Side effect profile 
No long-term data b 
Orlistat  
120 mg tid, 
before meals 
Oral 
Pancreatic lipase 
inhibitor 
Yes Yes -2.6%d  
 
-6.1%d 
 
Not absorbed  
Long-term data b 
Modest weight loss 
Side-effect profile 
Lorcaserin 
10 mg bid 
Oral 
5-HT2C serotonin 
agonist with little 
affinity for other 
serotonergic 
receptors 
Yes No -2.5%  -5.8% Mild Side effects 
Long-term data b 
Expensive 
Modest weight loss 
Phentermine/ 
Topiramate 
ER 
7.5 mg/46 
mg; 15mg/92 
mg indicated 
as rescue 
Oral 
(requires 
titration) 
Sympathomimetic 
Anticonvulsant 
(GABA receptor 
modulation, 
carbonic 
anhydrase 
inhibition, 
glutamate 
antagonism) 
Yes No -1.2%  -7.8% 
(Mid 
Dose) 
-9.8%(Full 
Dose) 
Robust weight loss 
Long-term data b 
Expensive 
Teratogen 
Naltrexone Opioid receptor Yes Yes -1.3%  -5.4%  Greater weight loss Moderately expensive 
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SR/ 
Bupropion 
SR 
32 mg/ 360 
mg 
Oral  
(requires 
titration) 
antagonist 
Dopamine & 
noradrenaline 
reuptake inhibitor 
Reduces food addiction 
Long-term data b 
Side-effect profile 
Liraglutide  
3.0 mg 
Injection 
(requires 
titration) 
 
GLP-1 receptor 
agonist  
Yes Yes -3%  -7.4% 
(Full dose) 
Side effect profile 
Long-term data b 
Expensive 
Injectable 
 
  
 Table 3:  Surgical Procedures for Treatment of Obesity 
 
 
Procedure Weight loss 
after 3 years 
Δ BMI (kg 
/m2) (95% CI)  
 
Effects on 
type 2 
diabetes 
remission 
(%) (95% CI)  
at  years –  
Mortality 
% (95% CI) 
<30 day 
>30day 
 
Re-
operation 
rate  
%(95% 
CI) 
 
Complications 
% (95% CI) 
Adjustable 
gastric 
banding (AGB) 
−11.43 
(−18.14 to 
−4.72) 
67.58 (49.51-
82.83) 
0.07 (0.02-
0.12) 
0.21 (0.08-
0.37) 
7.01 
(3.99-
11.24) 
7.80 (3.90-
13.00) 
 
Sleeve 
Gastrectomy 
(SG) 
−16.78 
(−20.57 to 
−12.99) 
85.53 (72.69-
94.07) 
0.29 (0.11-
0.63) 
0.34 (0.14-
0.60) 
2.96 
(1.70-
4.71) 
8.90 (5.60-
13.00) 
 
Roux-en-Y 
gastric bypass 
(RGB) 
−21.88 
(−27.96 to 
−15.79) 
92.83 (85.29-
97.21) 
0.38 (0.22-
0.59) 
0.39 (0.01-
0.86) 
5.34 
(4.48-
6.48) 
12.00 (7.30-
17.00) 
 
 
Data in table are from Chang (2014).  Note that for this analysis, surgical procedures were grouped: AGB includes 
laparoscopic gastric banding and Swedish band; SG includes sleeve gastrectomy and vertical banded gastroplasty; RGB 
includes laparoscopic and open procedures as well as biliopancreatic diversion with or without duodenal switch. 
 
 
  
Supplemental Table  Common side effects and contraindications and 
warnings for medications used to treat patients who are overweight 
or obese.  
Information is from US Product Label, except where noted.89-95  
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ 
Medication  Common Side Effects Contraindications and Warnings 
Phentermine 
15 -30 mg  
 
 Headache 
 Elevated Blood Pressure and 
Pulse 
  
 Insomnia 
 Dry mouth 
 Constipation 
 Anxiety 
 Contraindicated with history of 
cardiovascular disease 
 Use with caution in patients with 
even mild hypertension 
 Contraindicated with MAOIs, 
hyperthyroidism, glaucoma, history 
of drug abuse 
 Primary pulmonary hypertension 
(rare) 
 Hypoglycemia with diabetes 
 Only indicated for short-term use –
“a few weeks” 
Orlistat  
120 mg tid,  
 
 Steatorrhea 
 Oily spotting 
 Flatulence with discharge 
 Fecal urgency 
 Oily evacuation 
 Increased defecation 
 Fecal incontinence 
 Contraindicated in pregnancy 
 Warning: ↑cyclosporine exposure 
 Liver failure (rare) 
 Requires co-administration of 
multiple vitamin 
 Increased risk of gall bladder 
disease  
Lorcaserin 
10 mg bid 
 
 Headache 
 Dizziness 
 Nausea 
 Dry mouth 
 Fatigue 
 Constipation 
 Contraindicated in pregnancy 
 Use with caution with SSRI, SNRI, 
MAOIs, St John’s wort, Triptans, 
Bupropion, Dextromethorphan 
 Contraindicated in pregnancy 
Phentermine/ 
Topiramate ER 
7.5 mg/46 mg 
 Insomnia 
 Dry mouth 
 Constipation  
 Paresthesias 
 Dizziness 
 Dysgeusia 
 Contraindicated in pregnancy  
 Fetal toxicity; monthly pregnancy 
test suggested 
 Contraindicated with 
hyperthyroidism, glaucoma 
 Do not use with MAOIs or 
sympathometic amines 
 Acute myopia (rare) 
Naltrexone SR/ 
Bupropion SR 
32 mg/ 360 mg 
 
 Nausea 
 Constipation  
 Headache 
 Vomiting 
 Dizziness 
 Boxed warning: suicide risk in 
depression 
 Contraindicated in pregnancy 
 Contraindicated in seizure 
disorders, uncontrolled 
hypertension, glaucoma 
 Do not use with opiods, MAOIs 
 Hepatotoxicity (rare) 
Liraglutide  
3.0 mg 
 
 Nausea 
 Vomiting 
 Diarrhea 
 Constipation 
 Headache 
 Dyspepsia 
 Fatigue 
 Dizziness 
 Abdominal pain 
 Boxed warning: thyroid C cell 
tumors in rodents 
 Contraindicated with personal or 
family history of medullary thyroid 
cancer or multiple endocrine 
neoplasia. 
 Pancreatitis 
 Hypoglycemia in diabetes 
 Increased risk of gall bladder 
disease 
tid = three times a day; bid = twice a day; ER = extended release; SR = sustained release; MAOI = monoamine oxidase inhibitor; SNRI = 
Serotonin-norepinephrine Reuptake Inhibitor; SSRI = Selective Serotonin Reuptake Inhibito 
 
